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ABSTRACT 
Over the last 30 years the development of invasive methods to directly measure 
the haemodynamic impact of individual coronary stenoses on blood flow has 
enabled the identification of vessel-specific and lesion-specific ischaemia. 
Fractional flow reserve (FFR) is the most commonly used technique, largely due 
to the simplification brought by its pressure-only methodology. Despite the 
evidence accumulated demonstrating the benefits of FFR-guided decisions, its 
adoption remains low worldwide (6-8%) and a large proportion of patients with 
coronary artery disease (CAD) still undergo percutaneous interventions without 
any objective evidence of myocardial ischaemia. This is partly due to FFR’s 
reliance on the induction of coronary hyperaemia, a methodological step which 
adds time, cost and inconvenience for patients and clinicians. 
Recently, our group presented a novel invasive pressure-only methodology, the 
instantaneous wave-free ratio (iFR), which differs from FFR as it can be 
calculated at baseline, without the need for vasodilator administration. In its initial 
validation studies, iFR demonstrated a close diagnostic agreement with FFR and 
with invasive coronary flow. 
In this thesis, I will present a series of studies which aim to further evaluate the 
utility of iFR as an index coronary stenosis severity. Firstly, I will explore its 
diagnostic relationship with FFR in details and present a novel methodology to 
measure classification agreement between methods of clinical measurement. 
Secondly, I will evaluate the merits of utilising iFR and FFR in a common 
diagnostic pathway and quantify the potential benefits of such a strategy to spare 
patients from the need for vasodilator administration. Finally, I will investigate the 
5 
 
relationship between pressure-only indices (iFR and FFR) and coronary flow 
reserve, an extensively validated marker of prognosis in coronary disease.  
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1.1 Global burden of coronary artery disease     
Over the last 3 decades, more people have died from coronary artery disease (CAD) 
than from any other cause1. Whilst both incidence and mortality of CAD have been 
decreasing in the last decade in developing countries, they are expected to increase 
in developing nations as a result of increased longevity and urbanisation. Also, CAD 
is responsible for 10-18% of disability-adjusted life years (DALY) worldwide2. 
Optimal treatment of CAD requires a multi-dimensional approach which includes risk 
factor modification, pharmacological treatment and appropriate revascularisation of 
epicardial stenoses3. Therefore, accurate identification of those coronary lesions 
imposing limitation to coronary blood flow, causing symptoms of angina and 
increasing the risk of cardiac events is of crucial importance for patients and 
healthcare systems4-6.    
 
1.2 Coronary angiography and the limitations of anatomical assessment  
Soon after coronary angiography was established as a routine diagnostic method for 
CAD, its limitations to predict the functional significance of epicardial stenoses 
became evident7. The fluid dynamic mechanisms behind energy dissipation of 
coronary blood flow are complex and cannot be predicted by simplified angiography-
derived parameters such as stenosis length and percentage of luminal reduction 
[Figure 1.1]8. Therefore, diagnostic methods which directly measure the functional 
impact of coronary narrowings are essential for a more accurate prediction of 
symptoms, disease severity and prognosis in patients with CAD9-12. Also, it has been 
demonstrated that coronary revascularisation decisions which are based on the 
presence of myocardial ischaemia or coronary flow limitation are beneficial to 
patients when compared to decisions guided purely on angiography13-16. 
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Figure 1.1 Schematic representation of potential mechanisms for energy dissipation 
in coronary disease: Computational fluid dynamic (CFD) three-dimensional reconstruction 
of an idealized smooth model of coronary stenosis (A) and of a patient-specific anatomy (B). 
Streamlines of flow are artificially represented as yellow lines. The smooth model (70% 
cross sectional area reduction) was created with smooth luminal surface and symmetrical 
and gradual inlet/outlet stenosis transitions. As blood flow crosses the stenosis (1) a 
temporary drop in pressure is observed as energy is converted into velocity. However, the 
smooth surface and the lack of morphological asymmetries allow almost full pressure 
recovery distal to the stenosis, with minimal reduction in perfusion pressure (yellow colour, 
2). The patient specific model (with equal anatomical area reduction) shows potential 
sources of energy dissipation. As flow approaches the stenosis, part of it hits the abrupt inlet 
transition (3). Also, luminal roughness and wall irregularities lead to increased friction and 
flow disturbances outside (4) and, most importantly, inside the stenosis (5), which appears 
to be the main mechanism through which perfusion energy is lost. The abrupt outlet stenosis 
transition prevents flow re-attachment and leads to flow recirculation and disturbances (6), 
which also causes energy dissipation. Multiple sites of irreversible energy loss lead a 
reduction in perfusion pressure distal to the stenosis (orange colour, 7), leading to 
myocardial ischaemia. It can be therefore concluded that the reduction in cross sectional 
area per se is not the main limitation to coronary flow. This is the reason why, even when 
measured accurately, simple anatomical parameters such as percentage stenosis and 
minimal lumen area are weak predictors of physiology. The real anatomical obstacles to 
coronary flow (3-6) are not included in the standard criteria of disease severity.  
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1.3 Invasive coronary physiological assessment: lesion-specific quantification 
of functional disease severity 
Non-invasive diagnostic methods of functional disease severity (such as stress ECG 
and echocardiography and myocardial perfusion methods) play an important role in 
the diagnosis and risk stratification of patients with CAD17. However, they have two 
major limitations. Firstly, they do not provide information on vessel-specific or lesion-
specific ischaemia, which is relevant for patients with multi-vessel disease and when 
more than one coronary narrowing is present in a given coronary artery. Secondly, 
they do not quantify the amount of myocardial ischaemia or flow limitation imposed 
by stenoses. Therefore, invasive methods which use guide wires to directly measure 
the haemodynamic impact of an individual coronary stenosis can help clinical 
decision-making, by yielding information about which lesion(s) is(are) likely to be 
responsible for the patient’s symptoms, the magnitude of ischaemia created by such 
lesions and, importantly, how likely it is that the symptoms will improve when the 
obstruction is removed by the means of revascularization18, 19. 
 
1.4 Fractional flow reserve: the establishment of pressure-only assessment 
In stable coronary disease, myocardial ischaemia and symptoms of angina occur 
because of insufficient coronary blood flow for a given tissue demand20. Hence, 
invasive techniques which directly measure blood flow velocity with intra-coronary 
Doppler wires can provide valuable information about the underlying 
haemodynamics of lesions. However, since the development of the Doppler flow 
wire, adoption of flow-based methods in clinical practice has been largely restricted 
to research, mainly because of the demanding technical aspects of measuring 
invasive flow. Therefore, techniques which estimate coronary flow reduction by 
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measuring coronary pressure have been demonstrated to be more reproducible and 
easier to be applied clinically (Figure 1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although the first invasive measurement of coronary pressure gradients was 
made in the 1970’s21, it wasn’t until the mid 1990’s, when advances in 
technology permitted the development of small, sophisticated high fidelity wires, 
that invasive functional assessment of coronary disease started to become 
clinically relevant22, 23. Seminal work by Pijls et al24, 25 led to the development of 
fractional flow reserve (FFR), a pressure-only method of functional disease 
severity, which became the most adopted invasive technique in the 
catheterization laboratory. 
FFR is calculated as the ratio of distal (Pd) to aortic (Pa) coronary pressures during 
conditions of vasodilator-induced coronary hyperaemia. In animal models free of 
native coronary disease, FFR was demonstrated to be capable of predicting the 
proportional reduction in maximal flow caused by focal epicardial stenoses23. In 
clinical populations of patients with coronary disease, FFR demonstrates a good 
Figure 1.2: Measurement of coronary pressure and flow velocity  
When compared to coronary flow velocity (bottom panel), pressure is much easier to 
measure (top panel). In this example it took approximately 30s for the operator to obtain 
a good flow trace, whilst pressure reading remained robust across the whole trace. This 
simplification brought by pressure-only measurements largely explains the 
establishment of fractional flow reserve as the most commonly used invasive index of 
disease severity.    
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overall agreement with other functional modalities26. Finally, FFR has demonstrated 
its superiority over angiography alone to guide clinical decision-making in large 
clinical trials14, 27. The development of FFR, more than any other technique, has 
promoted a major shift in paradigm in the way cardiologists assess coronary 
stenoses severity in the cardiac catheterisation laboratory. The overall idea of 
revascularising all lesions which cause luminal reduction on angiography has been 
replaced by treating only those causing significant limitation to blood flow28.      
 
1.5 FFR dependency on the induction of coronary hyperaemia 
Indices of stenosis severity which are based on pressure gradients, such as FFR, 
are only physiologically meaningful (and hence clinical useful) if measurements are 
obtained under certain conditions (Figure 1.3): firstly, the underlying flow needs to be 
constant (or stable) for the resulting pressure drop to reflect only the severity of the 
stenosis being interrogated; secondly, the underlying flow needs to be of a minimal 
magnitude to allow for sufficient discrimination between stenoses of different 
severities29. 
At the time of the development of FFR, it was believed that the only way to achieve 
such physiological status (stable and sufficient flow) was via the induction of coronary 
hyperaemia, as baseline coronary flow was deemed too variable and of low 
magnitude. FFR, therefore, by definition, can only be calculated under conditions of 
maximal hyperaemia, which is achieved in clinical practice by the administration of 
potent coronary vasodilators (most commonly adenosine), either intravenously or via 
the intracoronary route30. 
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Figure 1.3: Understanding the need for stable and minimal underlying coronary flow 
for accurate pressure-only assessment of stenosis severity   
25 
 
1.6 Coronary flow reserve and prognosis stratification  
Coronary flow reserve (CFR), defined as the ratio of hyperaemic flow to baseline 
flow, is a flow-only index of disease severity which quantifies the capacity of the 
coronary circulation to increase flow upon demand. Decades of research have 
consistently demonstrated the diagnostic and prognostic values of CFR in 
patients with CAD. Whether measured invasively or non-invasively, CFR has 
been shown to be able to identify patients with myocardial blood flow impairment, 
predict prognosis and stratify which lesions may benefit from revascularisation11, 
57-62. More than any other physiological index of coronary disease severity, CFR 
has demonstrated its ability to predict hard events in patients with coronary 
disease, importantly death and myocardial infarction. Patients who demonstrate 
the capacity to double the amount of coronary flow upon demand (CFR >2) have 
excellent long term prognosis, regardless of the presence of other traditional risk 
factors, such as diabetes. Also, CFR’s ability to predict events appears to be 
stronger than other markers of ischaemia, such as regional wall motion 
abnormalities on echocardiography31 or the underlying FFR value of an 
epicardial stenosis32. CFR can therefore be seen as a safety marker in patients 
with CAD and an index against which novel diagnostic modalities should be 
tested.   
 
1.7 The baseline instantaneous wave-Free Ratio (iFR)  
1.7.1 The need for a novel vasodilator-free index 
Despite the robust evidence to support the use of  FFR over angiography to guide 
revascularisation decisions, its adoption worldwide remains low35, 36, estimated as 
10-15% in Europe, 6-8% in the US and less than 1% in most developing countries 
(Figure 1.4). Undeniably, this low adoption is partly caused by the need for 
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vasodilator administration during FFR calculation, a step which adds time and cost to 
the procedure and inconvenience for the operator33. Also, in some countries, 
adenosine, the most commonly used vasodilator, is prohibitively expensive or simply 
not available, which prevents the benefits of invasive physiological assessment to 
reach many patients with coronary disease worldwide. Also, the administration of a 
potent systemic vasodilator such adenosine during stress testing is not free from 
side-effects and can induce hypotension, bradycardia, bronchospasm and acute 
coronary syndromes34.         
Finally, despite the clear benefits of FFR over angiography in identifying functionally 
significant stenoses which could be amenable to revascularization, there remain 
approximately 30% of cases in which FFR disagrees in stenoses classification with 
CFR, the most important predictor of cardiac events in CAD35-37. This disagreement 
with underlying flow suggests there might be scope for improvement in the current 
pressure-only approach to lesion selection using FFR. 
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Figure 1.4: Estimated global adoption of fractional flow reserve in 2013 
Values in yellow represent the estimated utilization of fractional flow reserve to guide percutaneous intervention (%). 
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1.7.2 Initial development of iFR: the ADVISE study     
Recently our research group presented a novel index of coronary disease severity, 
the instantaneous wave-Free Ratio (iFR), which fundamentally differs from FFR as it 
can be calculated from baseline coronary haemodynamics, without induction of 
hyperaemia38. iFR is the ratio of distal (Pd) to proximal (Pa) coronary pressures 
(Pd/Pa) at a specific part of the cardiac cycle, the baseline diastolic wave-free period 
(Figure 1.5 and Figure 1.6).   
  
Figure 1.5: Wave Intensity Analysis and the diastolic wave-free period: 
Pressure and flow are linearly related during the baseline diastolic wave-free period. 
This provides the physiological basis for the development of the instantaneous wave-
free ratio (iFR) as an index of stenosis severity. 
29 
 
 
  
0 1000 2000 3000 4000 5000 6000
200
400
600
800
1000
1200
1400
1600
1800
A
P
a 
an
d
 P
d
 
P
re
ss
u
re
 
(m
m
H
g)
50
150
FFR = 0.74
B
C
iFR = 0.79
Pd wave-free period
Pa wave-free period
= iFR
4.6 4.7 4.8 4.9 5 5.1 5.2 5.3 5.4
x 10
4
1
1.5
2
2.5
3
x 10
4 Zoom in/out with mouse. Press any button to start acquiring data
4400 4500 4600 4700 4800 4900 5000 5100 5200 5300 5400
600
700
800
900
1000
1100
1200
1300
1400
1500
1600
Figure 1.6: The instantaneous wave-free ratio (iFR) 
iFR is calculated as a ratio of distal to proximal coronary pressures (Pd/Pa) at a specific 
period in baseline diastole – the wave-free period- without the need for hyperaemia 
induction  
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The physiological basis for iFR was described in the ADVISE study, which performed 
the first pilot comparison between iFR and FFR, using invasive coronary flow38. In 
ADVISE, iFR was found to have good agreement in stenoses classification with FFR 
across a wide spectrum of disease severity. Also, distal microvascular resistance 
during the baseline iFR window was found to be as stable as during whole cycle 
hyperaemia and FFR calculation. From ADVISE, these two initial encouraging 
findings set the foundations for further larger exploratory studies. 
 
1.7.3 iFR, FFR and magnitudes of distal microvascular resistance: the CLARIFY study   
A subsequent study from our group extended the initial analysis from ADVISE to 
explore the haemodynamics underlying iFR and FFR, particularly the magnitudes of 
distal coronary resistance achieved during calculation of both indices39. This was a 
crucial analysis, as historical animal data from early 1990’s suggested that FFR 
could provide better discriminatory power over baseline indices, because the 
induction of hyperaemia decreased distal microvascular resistance (and hence 
increased flow) by several fold23. Despite continuous development in FFR research, 
including its application in large outcome trials, the extent at which the induction of 
hyperaemia increases coronary flow in humans with coronary disease has never 
been explored in details. CLARIFY was therefore the first invasive study which 
evaluated the effects of adenosine on distal coronary resistance in patients 
undergoing FFR measurement. We found that the ability of adenosine to decrease 
resistance above baseline diastole was restricted to mild, not flow-limiting lesions. In 
stenoses which impose high resistance to blood flow (as measured by the 
hyperaemic stenosis resistance index HSR), baseline diastole offers a physiological 
environment with equal or even lower microvascular resistance than hyperaemia. 
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This finding provides strong physiological evidence to support the validity of baseline 
iFR, as it suggests that the magnitude of distal coronary resistance during baseline 
diastole is sufficiently low to enable identification of flow-limiting stenoses. 
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1.8 Aims of this thesis 
The aim of this thesis is to provide further physiological and clinical validation for 
the utilisation of iFR as a functional index of stenosis severity. 
Firstly, the relationship between iFR and FFR will be explored extensively in a 
larger and more clinically relevant sample. To that end, I evaluated the 
agreement in stenoses classification between iFR and FFR in patients 
undergoing routine FFR assessment in clinical practice.  
Secondly, I will investigate the applicability of a hybrid decision-making strategy, 
in which both iFR and FFR are used in the same diagnostic pathway. In this 
analysis, I will explore the vasodilator-sparing capacity of iFR and the potential 
benefits to patients and healthcare systems associated with the reduction in the 
need for adenosine administration and FFR calculation. 
Finally, I will further explore the underlying haemodynamics of both baseline iFR 
and hyperaemic FFR, using invasive coronary flow velocity and CFR as 
independent discriminators. In this final study, I will evaluate the agreement 
between pressure-only indices (iFR and FFR) and underlying CFR and quantify 
the magnitudes of underlying coronary flow achieved during their calculation.    
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2 MATERIALS AND METHODS 
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2.1 Funding 
My work on this thesis was funded, in the first year, by the Imperial College Charity Grant. 
Funding for the years 2 and 3 were obtained via a personal Clinical Research Training 
Fellowship from the British Heart Foundation (Grant FS/11/46/28861).   
2.2 Study sample 
The final samples of the studies included in this thesis were a result of international 
collaborations between Imperial College Healthcare NHS Trust and other centres with 
extensive experience in invasive coronary physiology. This allowed exchange of 
expertise and increased power for each study. Whilst I have personally collected data 
which resulted from recruitment of 45 patients from Imperial College Healthcare NHS 
Trust, I was responsible in each study for pooling all data from all centres and 
performing all required subsequent analyses, which I describe in details below.      
At our centre, potential patients were identified from the waiting list for coronary 
angiography at Imperial College Healthcare NHS Trust. Information about the study was 
provided at pre-assessment and consent was obtained at the day of the clinical 
procedure, once suitability for inclusion was confirmed. The study was approved by 
national and local ethics committees (NRES ref: 09/H0712/102 and 10/H0803/1; 
NCT01118481). 
2.3 Set-up in the catheterization laboratory  
2.3.1 Cardiac catheterization 
Cardiac catheterization was performed according to standard clinical practice. 5000-10000 
units of unfractionated intravenous heparin were given at the start of the procedure together 
with 300mcg-600mcg of intracoronary nitrates to minimize changes in epicardial artery 
diameters. Invasive physiological data was acquired after diagnostic angiography. 
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2.3.2 Aortic catheter 
All aortic recordings were made via a 6 French guiding catheter. Guide catheters offer 
better inner coating, have a larger lumen and allow better torque control of the wire by 
the operator.  
2.3.3 Medication 
Since most patients studied were being investigated for possible coronary artery 
disease, it was deemed unethical to stop any of the medications they were taking prior 
to the procedure. Before the insertion of any intracoronary wire, 5000IU of heparin was 
given intravenously to reduce the risk of thrombosis. Furthermore, the activated clotting 
time (ACT) was measured at regular intervals and maintained above 250 seconds. 
Intracoronary GTN (300mcg) was administered to each artery before physiological 
assessment was performed to ensure no epicardial artery spasm. 
 
2.3.4 Induction of hyperaemia  
Current clinically used indices of coronary stenosis and microvascular resistance are 
measured during the administration of adenosine. The clinically recommended dose 
varies according to its route of administration. Intravenously a dose of 140mcg/Kg/min of 
adenosine via femoral venous line is recommended; intra-coronary a dose of 120mcg of 
adenosine by rapid bolus injection directly into the target vessel. Only an intravenous 
route of adenosine administration was used when simultaneous pressure and flow 
velocity measurements were made. This was done to ensure adequate time was 
available to achieve the best possible flow velocity envelope which is especially 
challenging in vessels with severe stenoses. 
 
2.4 Data acquisition 
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2.4.1 Haemodynamic recording 
Pressure and flow velocity were measured simultaneously with a 0.014inch combined 
pressure and Doppler sensor-tipped wire (ComboWire® XT, Volcano Corporation, San 
Diego, CA). 
2.4.1.1 The ComboWire XT  
The ComboWire is a steerable guide wire which combines two different sensors. The 
guide wire has a diameter of 0.014" (0.36 mm) and a length of 185 cm. The CombTip 
type (model reference 9500) that was used in this study contains a pressure transducer 
and an ultrasound transducer, both mounted in a single housing at the tip of the guide 
wire (Figure 2.1). The ComboWire was connected to the ComboMap system via the 
patient interface module which conveyed the signals of Doppler and pressure from the 
wire to the console. 
 
Figure 2.1: The ComboWire XT 
 
2.4.1.2 Electrocardiogram 
Electrocardiogram (ECG) data was recorded throughout study. ECG analogue data was 
fed into the haemodynamic console. The ideal output lead was selected to ensure a 
dominant R wave was present. This is essential as the R wave provides the fiducial 
point against which the software would later identify each cardiac beat.        
 
0.014”
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2.4.1.3 Hemodynamic console 
The ComboMap system 6800 (Volcano Corporation, San Diego, CA) processes the 
information it receives from the ComboWire, pressure transducer (from the 
catheterisation laboratory table) and ECG (Figure 2.2). Data recorded for subsequent 
analysis included the ECG, proximal aortic pressure (Pa) obtained from the aortic 
catheter used for coronary angiography, distal aortic pressure from the ComboWire 
pressure sensor (Pd) and instantaneous peak coronary flow velocity from the 
ComboWire Doppler sensor (IPV).  All data was displayed in the console in real time 
(Figure 2.3). Pa, Pd, IPV and ECG were digitally stored in an .SDY file at a sampling 
frequency of 200Hz. Anonymized data was exported at the end of the procedure. 
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Figure 2.2: Haemodynamic console used for data acquisition (ComboMap system 
6800) 
 
 
 
 
 
 
 
 
  
Figure 2.3: Haemodynamic data displayed at the console during data acquisition 
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2.4.1.4 Aortic pressure measurement 
We used fluid-filled hollow guide catheters to measure aortic pressure (Pa) throughout 
the procedure. Pressure is transmitted through a tiny fluid column to an external 
pressure transducer, to which the fluid-filled system is connected. In order to maintain 
the highest level of quality of the pressure trace, the distance between the coronary 
artery to the pressure transducer was kept to the minimum and the catheter was kept 
free of bubbles. The pressure transducer was fixed to the catheter table to avoid 
erroneous readings of pressure due to height changes of the transducer. Before use, 
each of the fluid-filled catheters was zeroed at the right atrial level with the patient 
supine.  
The pressure waveform was displayed continuously on a screen to be viewed by the 
operator together with minimum, maximum and mean values of aortic pressure. The 
standard procedure in the catheterization laboratory is to mount the pressure transducer 
of the guiding catheter at a height of 5 cm below the sternum, which is estimated to be 
the location of the aortic root. As this is merely estimation and can be incorrect, pressure 
readings may be also be incorrect. Therefore, by adjusting the height of the pressure 
transducer small errors in pressure can be corrected; decreasing the level of the 
transducer increases aortic pressure, increasing the height of the transducer will 
decrease aortic pressure. This manoeuvre was only carried out if during the verification 
process of comparing the fluid-filled pressure reading with that of the guide wire (at the 
time when the guide wire is positioned at the tip of the guide catheter while sitting at the 
coronary ostium) there was a pressure difference between the two readings. This step is 
explained on the section on equalizing pressure. 
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2.4.1.5 Distal coronary pressure measurement 
The ComboWire XT 0.0 guide wire (Volcano therapeutics) was used to measure 
coronary pressure (Pd) and a new sterile wire was used for each patient. Calibration of 
the pressure wire was carried out outside the body, with the wire positioned and rested 
on the table, through an automated process by the ComboMap. Once this was done, the 
‘ready’ signal displayed on the touch screen enabled use of the wire. At baseline and 
with the wire outside the body, a check was carried out to ensure that Pd was reading 
zero pressure. If not, the wire was zeroed. Only then, was the wire removed from the 
spiral. Furthermore, to help with rotational movements and manipulation in the coronary 
arteries, the shapeable guide wire tip was carefully shaped using standard tip shaping 
practices. With experience, we found that for best results, the shaping of the tip had to 
be done in the direction of the sensor housing opening. Under fluoroscopic imaging, the 
wire was positioned in the coronary artery at the site of interest and on occasions torque 
was applied to facilitate this. 
 
2.4.1.6 Equalising pressure in the ascending aorta 
At the coronary ostium, the pressure displayed by both the fluid-filled system and the 
pressure wire were compared. At this point to ensure wire pressure was equal to aortic 
pressure the wire pressure was equalised to aortic pressure. The next step of the 
protocol was only followed once it was confirmed that there was no difference in the two 
pressures. A guide wire introducer was placed in the Y-connector to facilitate wire 
manipulations in the coronary artery. The space around the wire within the introducer 
may leak and lead to aortic pressure measurements which are below the actual 
pressure. Although in every case we checked that the introducer was not leaking, we 
took the extra precaution of making all measurements with the introducer out and the Y-
connector always locked in the closed position so that there was no leakage around the 
wire. 
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It should be noted that equalisation of pressure occurred in the aorta and therefore in the 
presence of a clear dicrotic notch on the pressure wave form. The presence of this notch 
was ensured throughout the measurement process to ensure no damping of aortic 
pressure was present which has been shown to result in inaccurate intra-coronary 
measurements.  
 
2.4.1.7 Checking for pressure drifting 
One problem encountered during some of the procedures was signal drifting. This is a 
phenomenon which is frequently encountered during pressure wire measurements and a 
drift of <5mmHg per hour has been previously regarded as acceptable (25). However, 
due to the magnitude of the measurements we were making we refused to accept any 
drift in the measurements. As a result after each of the measurements the pressure 
sensor was returned to its original position in the aorta (where equalisation was 
performed) to ensure there was no drift. If any drift was detected the measurements 
were repeated. If the wire continued to drift it was replaced. No post hoc correction of 
drift was therefore necessary.  
 
2.4.1.8 Coronary flow velocity measurement 
The ComboWire XT 0.0 guide wire (Volcano therapeutics) was used to measure 
instantaneous peak velocity of blood (IPV) simultaneously with Pd. A new sterile wire 
was used for each patient. Doppler velocity is measured approximately 5 mm from the 
tip of the wire. The pulsed Doppler beam angle is 45 degrees and insolates a sample 
volume of approximately 4 mm downstream of the Doppler probe. Fine rotational 
movements were carried out so that the Doppler beam captured the highest velocity. 
The intensity of the Doppler envelope was taken as indicative of this. Acquisition of the 
Doppler signal proved the most demanding aspect of the study acquisition process. With 
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experience we were able to get a strong, dense and steady signal even in the most 
challenging cases.  
 
2.4.1.8.1 Doppler calibration - Doppler spectrum input 
At each location, the wall filter function was used to reduce or eliminate low frequency 
noise returning in the Doppler spectrum when the transducer was near an artery wall. 
Available settings are 200, 400, 800 and 1600Hz, the optimum was found to be at 
400Hz and this setting was used in the majority of the cases. 
The IPV threshold is a signal to noise ratio, and establishes the signal threshold: signals 
below this level are considered noise and not displayed or used for flow measurements. 
The IPV threshold was set by optimizing the IPV envelope which is displayed as a blue 
envelope around the flow spectrum. This was adjusted manually in all patients and all 
vessels studied to ensure that the blue tracking envelope matched the outer edge of the 
velocity spectrum. A range of 0-3 was used for the majority of studies. 
 
2.4.1.9 Reproducibility of measurements 
Reproducibility of hemodynamic measurements has been demonstrated previously40. 
The mean and standard deviation of the difference between the separate 30-second 
recordings of blood pressure was 12.0±269 Pascal. The mean and standard deviation of 
the difference between the separate 30-second recordings of flow velocity was 0.007± 
0.022 m/s40.  
 
2.5  Post-acquisition haemodynamic data analysis 
Once exported from the console, haemodynamic data was imported to customized 
software written in Matlab (Mathworks, Inc.). This software was written by me using a 
combination of new coding with a foundation of codes from previous researchers in the 
group. The software automatically performed specific processes with the haemodynamic 
data: 
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2.5.1 Correction of pressure-flow delay 
For accurate analysis of phasic coronary haemodynamics it was vital that 
measurements of pressure and velocity were correctly aligned in time. Previous studies 
have demonstrated this delay to be 43ms (mean 42.5±3.8ms)40. This delay was 
subtracted from the timing of the pressure data in all subsequent analyses, so that both 
pressure and Doppler signals were synchronous. 
 
2.5.2 Data filtering 
All data was passed through a Savitzky-Golay smoothing filter. This filter is ideal for 
smoothing haemodynamic signals whose frequency span (without noise) is large. This is 
typical of haemodynamic data where it is common for peaks and troughs to occur rapidly 
in succession within a short time period. The Savitzky-Golay filter fits a polynomial to 
each frame of data to minimize the least of squares error. It is thus more effective at 
preserving pertinent high frequency components of a signal than standard averaging 
filters. However, whilst the Savitzky-Golay is very good at preserving high frequency 
components, it is less good than standard averaging filters at removing noise. Savitzky-
Golay polynomial order and frame width constants were set at 3 and 31 respectively in 
all data analysis. 
 
2.5.3 Calculation of coronary haemodynamic indices 
The software automatically calculated a series of haemodynamic indices, with minimal 
operator input. The diastolic iFR window was identified using fully automated algorithms 
acting over ECG-gated, time-aligned pressure traces, as described in the ADVISE 
study38. A screenshot example of the software used for analysis is presented in Figure 
2.4.  
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2.5.3.1 Definition of physiological indices  
 
Pa = Proximal (aortic) pressure (mmHg) 
Pd = Distal (coronary) pressure (mmHg) 
Fractional Flow Reserve (FFR) = 
  
  
 at whole-cycle hyperaemia 
Instantaneous wave-Free Ratio (iFR) = 
  
  
 at baseline iFR window 
Instantaneous wave-Free Ratio during adenosine administration (iFRa) = 
  
  
 at 
hyperaemic iFR window 
Baseline Flow = Mean baseline whole-cycle coronary flow velocity (cm/s) 
Flow FFR = Mean whole-cycle coronary flow velocity at stable hyperaemia (cm/s) 
Flow iFR = Mean coronary flow velocity during the baseline iFR window (mid-diastole) 
(cm/s)  
Coronary flow velocity reserve (CFVR) ** = 
                                    
                                  
  
Hyperaemic Stenosis Resistance (HSR) = 
                                               
                                      
  
 
 
 
Distal hyperaemic coronary resistance = 
                                           
                                      
  
 
 
 
Distal baseline iFR window resistance = 
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Figure 2.4: Screenshot of customized software used for off-line hemodynamic analysis: 
The operator selects the time window to be analysed and all indices are calculated automatically. 
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3  Classification performance of 
instantaneous wave-free ratio (iFR) and 
fractional flow reserve in a clinical 
population of intermediate coronary 
stenoses 
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3.1 Introduction 
 
Instantaneous wave-Free Ratio (iFR) is a recently proposed invasive pressure-
derived index of coronary stenosis severity.  It differs from fractional flow reserve 
(FFR) as it does not require the administration of vasodilators for its calculation. 
iFR is calculated from trans-stenotic pressure measurements as the ratio of distal 
to proximal coronary pressures during a specific wave-free period of the cardiac 
cycle, when microvascular resistance is intrinsically stable and minimised38.  
 
The physiological foundations of iFR and its diagnostic efficiency in identifying 
FFR-significant stenoses have been recently reported in the ADVISE study38.  As 
a validation study, ADVISE evaluated iFR’s performance across a broad range of 
coronary stenosis severities, which included tight and mild coronary narrowings, 
in the same line as pioneering studies of FFR24, 25, 41. However, in everyday 
practice, and in agreement with clinical practice guideline recommendations3, 5, 
42, functional intracoronary assessment of stenosis severity is predominantly 
used to interrogate intermediate stenoses with unclear severity. A critical 
difference of these two scenarios is that, in clinical evaluation of angiographically 
intermediate stenoses, FFR values tend to be distributed closer to the 0.80 
established cut-off. It is likely that these differences in frequency distribution of 
stenosis severity could influence the intrinsic agreement between repeated FFR 
measurements and the overall agreement between iFR and FFR on classifying 
coronary stenoses43-45 (Figure 3.1).  
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In the present study we evaluated the level of agreement between iFR and FFR 
in a cohort of patients with intermediate coronary stenoses investigated with 
pressure guide wires as part of their clinical assessment.  The agreement 
between iFR and FFR was interpreted in light of the intrinsic variability of FFR, 
and the underlying characteristics of FFR data distribution encountered in this 
registry. 
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3.2 Methods 
 
3.2.1 iFR and FFR data from this clinical registry 
 
3.2.1.1 iFR registry study population  
The study included 312 patients with 339 coronary stenoses that, as part of 
clinical management, required functional intracoronary assessment with pressure 
guide wires at three large European tertiary cardiac centres (Hospital Clínico San 
Carlos in Madrid, Spain; Guy’s and St Thomas’ NHS Foundation Trust, London; 
and the Academic Health Science System of Imperial College London, UK). 
Anatomical severity of coronary stenoses was measured using quantitative 
coronary angiography (QCA).  
 
3.2.1.2 Haemodynamic data collection and analysis 
Acquisition of physiological data for FFR calculation was performed according to 
conventional practice42 using commercially available FFR systems (RadiView 
console and PressureWire Certus, St. Jude Medical, Minneapolis, Minnesota; 
and  Combomap console and Prestige pressure guide wire, Volcano 
Corporation, San Diego, California).  Adenosine was used for the calculation of 
FFR; in 99% of the cases it was administered via a central line, with doses 
ranging from 140mcg/Kg/min to 200mcg/Kg/min; in the remaining 1% of the 
cases the intra-coronary route was used.  Digital data was extracted from FFR 
console platforms and processed off-line in a core laboratory (International 
Centre for Circulatory Health, National Heart and Lung Institute, UK) using a 
custom software package with Matlab (Mathworks, Inc., Natick, Massachusetts) 
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as described elsewhere38. It was possible to calculate iFR in all cases, using fully 
automated algorithms applied to the wave-free period over a minimum of 5 
beats, before adenosine administration, as previously described38 (Figure 1.6). 
 
3.2.2 FFR intrinsic variability data from landmark FFR reproducibility study 
The FFR reproducibility data from the DEFER study15 was obtained from a 
previously published scientific statement on physiological assessment of 
coronary stenoses from the American Heart Association, containing the 
correlation between 2 consecutive FFR measurements within 10 minutes in 325 
selected subjects42. Data was digitised using semi-automatic bitmap-to-digital 
software (Matlab, Mathworks, Inc.).  
 
3.2.3 Steps for establishing the overall classification agreement between iFR 
and FFR 
For the purpose of general understanding of our methodology, we have 
schematically divided this study in 5 steps, as summarised in the flowchart 
presented in Figure 3.2: 
 
The first step was to identify the optimal iFR cut-off (Step 1, Figure 3.2):  A 
receiver-operating characteristic (ROC) curve was applied to this iFR registry to 
identify the optimal iFR cut-off value to agree with an FFR of 0.8. Next, the FFR 
repeatability agreement was assessed (Step 2, Figure 3.2) using data from the 
DEFER reproducibility study.  Mean FFR values were divided in 0.05 quantiles, 
from 0.2 to 1 and the agreement (diagnostic accuracy) between the first and 
second FFR measurements calculated in each quantile. Agreement between 
FFR values was considered when both FFR values were below (or equal to) or 
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above the established cut-off of 0.80. Next, the agreement between iFR and FFR 
was assessed (Step 3, Figure 3.2) using data from this iFR registry, the same 
method to that described in step 2.  Then, the overall level of agreement (total 
diagnostic accuracy) between iFR and FFR and between repeated 
measurements of FFR was than calculated for the sample of this clinical registry 
(Step 4, Figure 3.2). For both iFR-FFR and FFR-FFR relationships, the total 
agreement was calculated by multiplying the agreement in each 0.05 quantile 
(from step 2 and 3) by the percentage of data points in each 0.05 quantile 
encountered in this registry.  Finally, an estimation of the overall iFR-FFR 
agreement and FFR repeatability agreement in different populations was 
performed using the same methodology applied in step 4 to estimate the overall 
level of agreement (total diagnostic accuracy) between iFR and FFR and 
between repeated measurements of FFR in different samples, from previous 
validation studies of iFR and FFR (Step 5, Figure 3.2). The frequency distribution 
of FFR values in the ADVISE trial, FFR reproducibility study and the landmark 
study which validated FFR against positron emission tomography (PET) were 
obtained from their original publications38, 41, 42.  
 
3.2.4 Statistical analysis  
Statistical calculations were performed using Matlab (Mathworks, Inc.) and 
STATA version 11 (StataCorp, College Station, Texas). The Hartigan’s Dip Test 
was used to test for unimodality for the samples of this clinical iFR registry, the 
FFR reproducibility study and the ADVISE study. The Hartigan’s Dip Test could 
not be applied to the FFR study against PET due to insufficient data points 
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across the entire range of FFR values.  The areas under ROC curves were 
compared using a nonparametric method46. 
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3.3 Results 
 
3.3.1 Patient characteristics of this clinical iFR registry 
Demographic, clinical and angiographic data of the iFR registry population are 
shown in Table 3-1. The mean diameter stenosis was 48% (standard deviation 
13%), indicating a predominantly intermediate anatomical stenosis grade. The 
interrogated stenoses were located most frequently in the left anterior 
descending artery (71%). The vast majority of patients presented with stable 
symptoms; in 7 % of cases, the pressure guide wire was used to interrogate non-
culprit stenoses in the context of an acute coronary event. There were no 
complications related to pressure guide wire interrogation of the stenoses. 
Analysis of the registry data revealed a unimodal distribution of FFR values with 
mean 0.81 (standard deviation 0.09) and median 0.82, with a preponderance of 
intermediate physiological severity: 71% of FFR values fell between 0.7 and 0.9 
and only 10% were < 0.7. The Hartigan’s Dip Test confirmed the unimodality of 
the data (dip test=0.027, p=0.1).  
 
3.3.2 Identification of optimal iFR cut-off  
To match an FFR value of 0.8, the ROC curve identified an optimal iFR cut-off 
value of 0.89. The area under the ROC curve for iFR was 0.86 (Figure 3.3), 
whilst for mean resting Pd/Pa was 0.80 (p=0.01). For an FFR value of 0.75, the 
ROC curve identified an optimal iFR cut-off value of 0.79.   
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3.3.3 Assessment of the agreement between iFR and FFR after accounting for 
the intrinsic variability of FFR  
 
3.3.3.1 Per-range classification agreement between repeated FFR measurements  
The FFR reproducibility study reveals the classification agreement between the 
first and second FFR measurements (the ability of both measurements to classify 
a lesion as significant or not based on a 0.8 cut-off). This repeatability agreement 
is shown in Figure 3.4 for each 0.05 quantile of the disease spectrum. In general, 
the ability of the 1st FFR measurement to agree with the classification of the 
second FFR measurement was strong across almost the whole range of disease.  
However, close to its established 0.80 cut-off, the FFR repeatability agreement 
fell, reaching a nadir of around 50%. Overall, for the population of this clinical iFR 
registry, the level of classification agreement between repeated FFR 
measurements was 85%.  
 
3.3.3.2 Per-range classification agreement between iFR and FFR 
The classification agreement between iFR and FFR (their ability to both classify a 
lesion as significant or not based on a 0.89 and 0.8 cut-off, respectively) is 
shown in Figure 3.5 for each 0.05 quantile of the disease spectrum. iFR - FFR 
categorisation agreement followed a similar pattern to the agreement of repeated 
measurements of FFR. iFR agreement with FFR was strong (100%) across 
almost the whole range of disease, except for the zone around their established 
cut-off where intrinsic FFR-FFR classification agreement was also lowest. 
Overall, for the population of this clinical iFR registry, the level of classification 
agreement between iFR and FFR was 80%.  
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3.3.4 Overall agreement between iFR and FFR in this clinical registry 
When the intrinsic variability of FFR is taken into account, the overall level of 
classification agreement between iFR and FFR in this registry population is 94% 
(80% observed iFR – FFR agreement as a fraction of the 85% FFR repeatability 
agreement) (Table 3-2).  Amongst the stenoses classified as non-significant by 
iFR (> 0.89) and as significant by FFR (≤ 0.8), 81% had associated FFR values 
located within the FFR “gray-zone” (0.75 - 0.8) and 41% within the 0.79 - 0.80 
FFR range.   
 
3.3.5 Overall agreement between iFR and FFR across different populations 
To assess the agreement between repeated FFR measurements and between 
iFR and FFR in populations with different distributions of FFR values, 
comparisons were made for the samples of the ADVISE study, the FFR 
reproducibility study and the FFR-PET study, using the same methodology as 
applied to this clinical registry. The population characteristics of these studies are 
summarised in Table 3-2 and their frequency distribution of FFR values is 
presented in Figure 3.6, with a comparison histogram of this clinical iFR registry. 
The overall level of classification agreement between iFR and FFR in different 
studies is presented in Table 3-2 and Figure 3.7. The magnitude of agreement 
between repeated FFR measurements and between iFR and FFR changes 
significantly depending on the underlying population studied. However, across all 
different samples, when the intrinsic variability of FFR is taken into account, iFR 
accuracy is almost identical, ranging from 94% to 96% (Table 3-2).  
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3.4 Discussion 
The present study finds an excellent classification agreement between iFR and 
FFR in a registry population that is formed by coronary stenoses with 
predominantly intermediate physiological and angiographic severities, the most 
frequent clinical context of FFR use. The agreement between iFR and FFR was 
analysed taking into account the intrinsic variability of repeated FFR 
measurements (from DEFER) in the same population. We have also found that 
the close relationship between iFR and FFR is maintained across populations 
with different distributions of FFR values, such as in previous validation studies 
of FFR and iFR. The overall agreement between iFR and FFR mirrors the 
agreement between repeated FFR measurements and varies significantly 
depending on the type of population being studied. However, for multiple types of 
population distribution, if the intrinsic variability of FFR is accounted for, iFR 
accuracy ranges from 94% to 96%.  
 
 
3.4.1 iFR and FFR: continuous variables interpreted dichotomously 
Despite the pressure gradient across a coronary stenosis being a continuous 
variable, assessment of stenosis severity with FFR is interpreted dichotomously 
(“significant” versus “non-significant”). One of the consequences of comparing 
two techniques that use dichotomous classification based on continuous values, 
such as FFR and iFR, is that the classification agreement between 
measurements will decrease when the values studied are close to the 
established cut-off (i.e. 0.8 for FFR). This concept, which is schematically 
depicted in Figure 3.1, is valid for comparisons between techniques (iFR versus 
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FFR) and, as we found in this present study, also affects the repeatability 
performance of an index (repeated FFR measurements). For instance, a small 
difference between measurements near the FFR cut-off value of 0.80 (for 
example, 0.79 versus 0.81) will have a direct effect on the stenosis classification. 
The same absolute difference in measurements when encountered away from 
the cut point (for example 0.50 versus 0.52, or 0.95 versus 0.97) will have no 
impact on the classification of a lesion. Figure 3.4 illustrates how the agreement 
between 2 repeated FFR measurements decreases around its established cut-off 
value. This observation is of paramount importance, since comparisons against 
FFR (newly proposed modalities such as iFR or even established techniques 
such as intravascular ultrasound) cannot, on average, perform better than FFR 
would perform against itself47. This phenomenon also demonstrates that, despite 
contrary belief48, a coronary pressure index sometimes can lie – even to itself.         
 
3.4.2 Effects of data distribution on overall agreement between iFR and FFR 
As a consequence of the above phenomenon, the frequency distribution of 
values in any study population has a major influence on the overall classification 
agreement between tests. Direct comparison of the overall percentage 
agreement (total accuracy) between tests is therefore only valid when applied to 
samples with the same type of data distribution. To circumnavigate this we 
applied a method which allows the overall agreement between iFR and FFR to 
be estimated in any type of data distribution and interpreted in the context of FFR 
intrinsic variability in the same sample. First, we demonstrated that within each 
quantile of physiological disease severity, the agreement between iFR and FFR 
follows a similar pattern to the intrinsic or intra-technique agreement of FFR 
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(Figure 3.4 and Figure 3.5). Subsequently, we calculated the overall agreement 
(or total accuracy) between iFR and FFR and the overall self-agreement (intrinsic 
accuracy) between repeated FFR measurements for the population encountered 
in this clinical registry. Finally, we extended this analysis to other populations, 
with different distributions of FFR values and demonstrated that iFR and FFR 
have a level of agreement which is as close as the FFR intrinsic agreement, 
when comparisons are made in the same type of population.  
 
3.4.3 iFR performance in a representative clinical population 
iFR was first tested as a diagnostic index in the ADVISE study. Being a 
methodological validation study, the main aim of ADVISE was to test iFR 
performance using FFR as a reference, over a wide range of stenosis severity. 
Indeed, 41% of the patients in ADVISE had FFR values < 0.7. This pattern of 
distribution, with an almost equal proportion of significant and non-significant 
stenoses, is a common feature of validation studies, including those which 
compared FFR against invasive coronary flow24, non-invasive functional tests25 
and positron emission tomography41. The ADVISE study documented a high 
level of agreement between iFR and FFR, setting the foundations of iFR as a 
coronary diagnostic modality. 
 
This registry constitutes a second step in the validation of iFR, applied in this 
occasion to a clinically representative population of individuals undergoing 
coronary physiological assessment in the catheter laboratory.  Although one of 
the messages arising from the FAME study14 was that even angiographically 
severe stenoses may have an associated FFR > 0.80, most physicians currently 
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limit the use FFR to the evaluation of angiographically intermediate stenoses, in 
agreement with the recommendation made by clinical practice guidelines3, 5, 42. 
This attitude is reflected in the characteristics of clinical cohorts, formed 
predominantly by physiologically intermediate stenoses. In the case of this 
clinical iFR registry the distribution of FFR data revealed that most FFR values 
(81%) fell between 0.60 and 0.90 (Figure 3.6), a pattern consistently shown in 
data from the three participating institutions. In this population of physiologically 
intermediate coronary stenoses, iFR maintained excellent classification 
agreement with FFR.  
 
3.4.4 The effects of data distribution on the optimal iFR cut-off 
In this clinical iFR registry, the optimal established cut-off value for iFR to identify 
stenoses with FFR of 0.80 was 0.89. This value is higher than the 0.83 optimal 
iFR cut-off observed in the ADVISE study but similar to the one observed in other 
studies comparing iFR and FFR in clinical populations49. As these cut-offs were 
identified using receiver-operating characteristic curves, accurate determination 
is highly dependent on adequate powering around the cut-off.  As this iFR 
registry had the majority of its lesions in the intermediate zone (81%), it is both 
reflective of the population in which such physiological assessments are routinely 
made, and is well powered to explore the iFR cut-off best reflecting FFR 0.8.  
Therefore, the iFR 0.89 cut-off represents the value of iFR which will more often 
agree with dichotomous classification of stenoses by FFR in clinical populations, 
and can therefore be considered the best iFR cut-off to identify 0.8 FFR stenoses 
in clinical practice.  
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3.5 Clinical implications  
Supported by multiple clinical studies demonstrating the benefits of physiology-
guided revascularisation, FFR utilisation has expanded significantly over the 
recent years and has culminated in recent proposals of interrogating every 
suitable stenosis, irrespective of its angiographic severity14, 15, 50. However, FFR 
is performed in only 6% of all coronary intervention procedures in the United 
States3. Undoubtedly, the need for adenosine administration is a contributor to 
this low adoption rate. As iFR is a pressure-derived index which does not require 
adenosine administration for its calculation, it is an attractive tool for the 
interventionalist, since it may simplify even further the utilisation of coronary 
physiology in the cardiac catheterisation laboratory. The idea of adenosine-free 
interrogation of coronary stenoses is also supported by recent demonstration that 
resting coronary haemodynamics can be used to infer the physiological 
significance of coronary lesions51.    
 
3.5.1 Data distribution of future iFR and FFR studies with clinical outcomes 
We believe that our results highlight the foremost importance of knowing the type 
of data distribution when quoting the overall performance of diagnostic tests such 
as accuracy and predictive values. For a valid interpretation of the 
meaningfulness of study results, we suggest that future trials, especially those 
evaluating clinical endpoints15, 27 such as FAME II study, present their data 
distribution for universal comparison.   
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3.6 Limitations 
Our study has limitations. The investigators had no control over the technique for 
measuring FFR across all three institutions. The recording of each FFR trace 
was performed relying solely on the clinicians’ expertise, which could potentially 
increase the chance for measuring error. However, this real-life method of data 
collection helps to strengthen the external validity of our results and its 
interpretation directly into clinical practice. 
This registry included patients in whom FFR was performed using either 
intravenous (99%) or intracoronary (1%) routes. Whilst differences in 
methodology may introduce theoretical differences between the groups, these 
differences are small, and reflect the real world assessment practices of the 
institutions in the study.  
Finally, iFR was compared to FFR within the same digital pressure trace, whilst 
the FFR intrinsic variability was established in repeated FFR measurements, 10 
minutes apart. It is unknown whether this time delay could influence the iFR-FFR 
relationship. iFR reproducibility studies are ongoing and will help clarify this 
discussion.   
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3.7 Conclusions 
iFR demonstrated a high level of classification agreement with FFR in a large 
group of patients with intermediate coronary stenoses, typical of individuals 
undergoing cardiac catheterization and invasive coronary physiological 
assessment. The agreement between iFR and FFR mirrors the intrinsic 
agreement of repeated FFR measurements when the same sample is being 
studied.  
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3.8 Tables  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EF = Ejection Fraction; CAD = Coronary artery disease; LAD = Left anterior descending artery; 
LCx = Left circumflex artery; RCA = Right coronary artery; LMS = Left main stem; SD = Standard 
deviation of the mean. Diagnosis of diabetes, hypertension, hypercholesterolaemia and chronic 
kidney disease was obtained from the history described in the medical notes. Smoking history 
includes current and previous cigarette smoking. 
  
No. of stenoses
Age, yrs ± SD
Male, n (%)
Co-morbidities, n (%)
Diabetes
Hypertension
Hypercholesterolaemia
Smoking history
Chronic kidney disease
Severe LV dysfunction 
(EF < 30%)
Clinical presentation, n (%)
Stable angina
Unstable angina
Coronary anatomy, n (%)
Single vessel CAD
Multivessel CAD
LAD
LCx
RCA
LMS
Proximal vessel
Diameter stenosis, % ± SD 
Reference vessel, mm ± SD 
Adenosine route, n (%)
Intravenous
Intracoronary
2.9 ± 0.6
332 (98)
7 (2)
241 (71)
44 (13)
44 (13)
10 (3)
48 ± 13
162 (48)
7 (2)
315 (93) 
 24 (7)
264 (78)
75 (22)
237 (70)
152 (45)
24 (7)
Table 1. Patient Demographic Data 
62 ± 10
261 (77)
105 (31)
210 (62)
339
Table 3-1: Patient Demographic Data 
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SD = Standard deviation of the mean 
   
iFR clinical registry 10 % 94 % (80/85)
FFR reproducibility 
study
36 % 94 % (86/91)
ADVISE study 41 % 94 % (88/93)
FFR - PET study 73 % 96 % (96/100)
iFR 
accuracyMean FFR 
± SD
14 %
0.81 ± 0.09
0.75 ± 0.14
0.72 ± 0.2
46 %
41 %
Distribution of
 FFR values
Population from
100 %
80 %
86 %
88 %
96 %
85 %
91 %
93 %
Repeated FFR 
measurements
Overall classification 
agreement between
FFR < 0.7 FFR 0.7 - 0.9
iFR and FFR
(observed)
0.63 ± 0.19
71 %
Table 3-2: Observed and adjusted iFR-FFR agreement in different populations 
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3.9 Figures 
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Figure 3.1: Classification agreement between two measurements depends on the data 
distribution 
The level of agreement between two measurements - when they are both “significant” or 
“non significant” – will vary within each range of disease severity (from mild to severe), 
depending on how close the data points are to the established cut-off (clusters of black 
dots). The overall agreement between them (the overall diagnostic accuracy) will therefore 
be influenced by the data distribution of the sample and depend on the proportional number 
of data points away from/close to diagnostic cut-off. 
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Step 1 Identification of ideal iFR cut-off using AUROC 
Step 2
Calculation of per-range agreement between 
repeated FFR measurements (from DEFER 
reproducibility data)
Step 3
Calculation of per-range agreement between iFR 
and FFR (using data from this iFR registry)
Step 4
Calculation of  the overall iFR vs FFR agreement for 
the population of this iFR clinical registry, adjusted 
for FFR intrinsic variability
Step 5
Calculation of  the overall iFR vs FFR agreement in  
different populations, adjusted for FFR intrinsic 
variability
Figure 3.2: Study flowchart 
Overview of study methodology 
67 
 
  
 
  
 
        
  
  
 
 
 
 
 
 
 
  
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1 - specificity
Se
n
si
ti
vi
ty AUROC: 0.86
Figure 3.3: Area under receiver-operating characteristic curve (ROC). 
Classification agreement between iFR and FFR in this clinical iFR registry, 
demonstrated using the area under the receiver-operating characteristic curve (FFR 
cut-off 0.8). The optimal iFR cut-off identified for the population of this study was 
0.89. 
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Figure 3.4: Per-range agreement between repeated measurements of FFR 
The top panel is a scatter plot of two repeated FFR measurements, taken 10 
minutes apart, digitised from reference 5. Bottom panel reveals the level of 
agreement (“diagnostic accuracy”) between the two measurements for each 
quantile of disease (from 0.2 to 1 in bands of 0.05). At extremes, agreement is 
excellent (100%). Close to the established cut-off, however, FFR starts to disagree 
with itself, with its intrinsic accuracy falling to approximately 55%. Gray dots in 
bottom panel mark the centre of each 0.05 quantile. Agreement between FFR 
values was considered when both FFR values were below (or equal to) or above 
the established cut-off of 0.80. 
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Figure 3.5: Per-range agreement between iFR and FFR 
The top panel is the scatter plot of iFR and FFR values from this clinical iFR 
registry. Bottom panel reveals the level of agreement (“diagnostic accuracy”) 
between the iFR and FFR for each range of disease (from 0.2 to 1 in bands of 
0.05). At extremes, agreement is excellent (100%). Close to their established cut-
offs, however, iFR-FFR classification agreement falls significantly. Gray dots in 
bottom panel mark the centre of each 0.05 quantile. Agreement between iFR and 
FFR values was considered when both tests were below (or equal to) or above 
their established cut-off. 
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Figure 3.6: Distribution of data in different FFR studies 
Frequency histograms reveal the unimodal type of data distribution of this clinical iFR registry, 
with predominantly higher FFR values (top left). This contrasts with the bimodal pattern of data 
distribution observed in the FFR reproducibility study (lower left); the more widely spread data 
seen in the ADVISE study (bottom right); and with the extreme type of distribution from the 
study which validated FFR against PET (top right). These contrasts highlight the differences 
between the study populations of methodological validation studies and patients undergoing 
routine coronary physiological assessment in clinical practice included in this iFR registry. Each 
bar represents one 0.05 FFR quantile and the symbol (*) identifies the most frequent FFR 
quantile in each population.  
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Figure 3.7: Overall classification agreement between iFR and FFR 
Top panels are the per-range agreement charts (from Figures 4 and 5) 
for iFR versus FFR (left) and repeated FFR measurements (right). The 
overall level of agreement (or total accuracy) between iFR and FFR and 
the intrinsic agreement of FFR are derived for different types of data 
distribution (left histograms, from Figure 6). In clinical samples such as 
this iFR registry (A), where values are distributed unimodally around the 
cut-off point, both iFR-FFR and FFR-FFR level of agreement are lower 
than those observed in samples where data is distributed bimodally, 
away from the cut-off area (B and D) or more widely (C). Agreement was 
considered when both tests were below (or equal to) or above their 
established cut-offs 
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4 The V-test: a novel, sample-independent 
statistical approach to describe agreement 
between methods of clinical measurement  
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4.1 Introduction 
In chapter 03, a new approach to compare diagnostic accuracies between iFR 
and FFR in different samples was introduced. In this study, this new statistical 
concept is explained in details using a simplified model of cardiovascular 
disease, which aims to demonstrate its utility in other areas of cardiology and 
clinical medicine.    
The performance of a clinical diagnostic test is often quantified by its diagnostic 
accuracy, and the directly-related sensitivity, specificity and predictive values52. 
Physicians often choose diagnostic methods based on their published diagnostic 
accuracy, an example of a statistical concept having a direct influence in patient 
care and even equipment purchase53. However, relying on diagnostic accuracy 
as an ideal measure of a test’s performance may forget a serious limitation, 
which is that for any given test and its reference gold standard, diagnostic 
accuracy can have any value from 50% to 100% depending on whether the 
sample studied is formed by intermediate or extremes forms of disease.  
Almost all clinically useful biological measurements are fundamentally 
quantifiable as continuous variables, such as serum sodium, plasma glucose and 
blood cholesterol. For clinical convenience, however, many are interpreted 
qualitatively, by a dichotomous classification into normal versus abnormal, based 
on a fixed cut-off. For instance, although serum levels of cholesterol can be 
quantified and displayed across a wide spectrum of values, patients are usually 
given a diagnosis of “hypercholesterolaemia or not” based on a fixed cut-off 
value. Dichotomising results into positive versus negative is common in daily 
clinical practice because of the perceived pressure of information overload, and 
sometimes with the reason given that clinical decisions are themselves 
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dichotomous (treat versus not treat). However, dichotomising quantitative data of 
diagnostic methods has consequences that may not have been considered and 
may be extremely undesirable54. 
 
4.1.1 Dependency of accuracy on distribution of patients 
Classification agreement between two methods of measurement is called 
diagnostic accuracy if one test is considered the reference gold standard. Rarely 
considered is how largely this value depends on the distribution of disease 
severity is the sample of patients studied (Figure 4.1). In short, very severely 
diseased and very healthy individuals are likely to be concordantly classified by 
both tests as positive or negative. A sample consisting of such extremes is likely 
to show a high diagnostic accuracy that may even approach 100%. In contrast, in 
the intermediate zone of disease severity, near the boundary between normal 
and abnormal, tests will always show classification disagreement. Naturally, 
therefore, samples formed predominantly by intermediate values are likely to 
show diagnostic accuracy values which could nadir close to 50%. 
Even worse is the situation when the two tests report values in the same physical 
units and are of potentially equal status, prompting the average of the two tests 
to be used as the consensus marker of severity, as recommended by Bland and 
Altman. For patients just at the boundary on this “average-of-two” scale, 
whenever one test is positive the other test must be negative. Thus for these 
individuals diagnostic accuracy is forced to be 0%. 
Mixtures of patients from these types, and other types in between, can generate 
any degree of diagnostic accuracy from 100% down to 50% for all diagnostic 
tests and definitions of severity.  
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4.1.2 Pioneering studies and clinical samples  
Studies which first evaluate diagnostic methods are often performed in samples 
whose distribution is very different from the populations in which the test will be 
applied in clinical practice55, 56. Commonly, pioneering research is performed in 
patients who either definitely have or definitely don’t have a condition, in a “case-
control” fashion. However, if the focus is on diagnostic accuracy (and the related 
indices sensitivity, specificity, predictive values and receiver-operator 
characteristic (ROC) curves), researchers may unknowingly be presenting values 
that cannot be directly compared between studies, nor are applicable to routine 
clinical practice.  
We give a practical example of why a single value of diagnostic accuracy cannot 
be a universal measure of a test performance, because of extreme dependence 
of the accuracy upon where in the spectrum the patients are drawn from.  
We then introduce the V-test, a simple visual approach to demonstrate 
classification agreement between methods of measurement, which is easy to 
calculate and interpret, and allows diagnostic accuracy to be derived for any 
sample distribution. 
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4.2 Practical example: a new diagnostic method for the screening of 
hypercholesterolaemiaϒ 
Imagine investigators developed a new method to measure serum cholesterol 
which utilizes an infra-red scan of the finger and yields an immediate value. The 
expectation was that this new test (Cholrapid) could be used in the primary care to 
screen for hypercholesterolaemia without the need for a needle or formal 
laboratory test, and would enable identification of patients at high risk of 
cardiovascular events and lead to early initiation of therapy. 
A landmark, large validation study was required before its implementation in 
clinical practice, so Cholrapid had to be tested against the gold-standard method 
of measuring cholesterol in the biochemistry laboratory (Cholgold). The landmark 
study tested Cholrapid performance across a wide range of cholesterol values. 
Therefore, 238 patients were recruited from multiple clinical settings: healthy 
young volunteers with no history of cardiac disease, patients with multiple risk 
factors from a cardiovascular clinic and patients from a specialised 
hyperlipidaemia out-patient service. For the purpose of diagnostic classification, 
a cholesterol result of 5.7 mmol/L¥ or above was considered 
hypercholesterolaemia.  
The results of this final clinical study confirmed early expectations, with Cholrapid 
showing an accuracy of 95% to diagnose hypercholesterolaemia, with a 
sensitivity of 95% and an area under the ROC curve of 0.99. Figure 4.2A shows 
a scatter plot between the two methods and summarizes Cholrapid diagnostic 
performance. 
As a result, Cholrapid was approved to be implemented in a large primary care 
unit for a period of trial. For one year, patients from the community with at least 
one risk factor for cardiovascular disease started having their cholesterol 
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measured with Cholrapid. During this initial clinical evaluation, however, blood 
samples were still sent for standard laboratory analysis (Cholgold), for a period of 
real-world comparison. 
At the end of the first year of its utilisation, investigators re-evaluated Cholrapid 
diagnostic performance, comparing it against the same gold standard 
measurement Cholgold.  The results of this second, retrospective analysis were 
very disappointing. Cholrapid diagnostic accuracy to identify patients with 
hypercholesterolaemia fell to 83%, with a significant drop in sensitivity (84%), 
and an area under ROC curve of 0.89 (Figure 4.2B). As a result, a primary care 
safety committee decided to temporarily withhold Cholrapid utilisation until a 
comprehensive assessment of its reliability was carried out. 
The health authority look into the reasons for such discrepancy between the final 
validation study and its first year of implementation, but found nothing obvious: 
the technique applied was exactly the same, with comparisons made against 
Cholgold tested in the same biochemistry laboratory. 
 
4.3 Diagnostic accuracy: a population-dependent measure of agreement   
The fundamental relationship between Cholrapid and Cholgold remained unaltered 
in the two studies, as shown by the degree of vertical dispersion of values (raw 
measurement disagreement) in both scatter plots (Figure 4.3A). The stable 
relationship between the two methods can also be demonstrated in the form of 
Bland-Altman plots (Figure 4.3B), which reveals that the limits of agreement were 
very similar in the two studies57.  
Therefore, the significant reduction in Cholrapid diagnostic performance between 
studies (accuracy, ROC curve, sensitivity, etc) can be entirely explained by how 
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differently cholesterol values were distributed in the two samples (Figure 4.4). 
The specific explanation is that the studies differed severely in what proportion of 
patients had cholesterol values close to the diagnostic cut-off of 5.7mmol/L: 
whilst the final validation study included patients with a wide range of cholesterol 
values (and so a large proportion of them far away from the cut point), the 
primary care study was mainly formed by patients with intermediate values of 
cholesterol, straddling the cut-off value, i.e. the region where most 
disagreements occur. Differences in the distribution of cholesterol values, rather 
than in the actual measurement performance of Cholrapid, were responsible for 
the different accuracy values (Figure 4.1).     
Our example highlights two important principles for any diagnostic modality. First, 
for the relationship between any two methods of clinical measurement, there are 
no universal values of diagnostic accuracy, sensitivity, specificity, predictive 
values or ROC curve, because classification agreement between methods can 
change greatly with the distribution of the patient sample. These parameters are 
only meaningful to demonstrate the effects of the raw measurement 
disagreement between the two methods (vertical scatter, Figure 4.3) in a specific 
population when a specific classification cut-off is used to define what is normal / 
abnormal.  
Secondly, pioneering work very commonly uses a much wider spread of patients 
than is found in routine clinical practice25. While the desire to examine the whole 
spectrum is understandable, clinicians should realise that clinical populations 
often have substantially more patients in the middle zone, and therefore would 
show a much lower rate of classification match or diagnostic accuracy58. 
Therefore, when choosing a diagnostic modality based on its reported diagnostic 
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accuracy, an eye should be kept on whether this value was obtained from a 
clinically representative sample or instead one that artificially enhanced 
accuracy, even if unintentionally.    
 
4.4 The V-test: a sample-independent method to measure classification 
agreement between tests 
The concept of diagnostic accuracy is appealing because it gives clinicians a 
standardised, dimensionless measure of how good a test is (out of 100%)59. 
Neither the simple measurement of the vertical scatter in a correlation plot (the 
true measure of numerical disagreement) nor the calculation of limits of 
agreement using with Bland-Altman plots are as instantly appreciated by all 
clinicians.  However, diagnostic accuracy and related parameters are flawed 
when quoted in isolation because values from one study may have no 
relationship to values in another cohort whose patients are distributed differently.     
We therefore present a way to combine the simplicity and clinical usefulness of 
parameters such as diagnostic accuracy with an additional information which 
makes it easy to apply to any population.   
 
4.5 The V-plot: a display of per-quantile accuracies 
To circumvent this sample-dependency, instead of simply calculating an overall 
value of diagnostic accuracy for the whole study population, we should calculate 
the classification agreement between methods in each part of the spectrum of 
disease severity. This results in several per-quantile values of “accuracies”, 
which can be displayed across the entire range of disease severity to generate a 
V-shaped plot, which gives name to the test (Figure 4.5). The V-plot has this 
shape because, as demonstrated in Figure 4.1, patients at extremes usually 
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show good diagnostic agreement between modalities producing plateaus near 
100% at the left and right, but close to the classification cut-off agreement 
plunges to around 50% (or even lower if severity is defined by the average of the 
two tests). 
The V-plot is, therefore, a universal fingerprint of per-quantile classification 
agreement between two methods of measurement, which can be expressed 
independently of the distribution of values of the underlying sample. This can be 
demonstrated by displaying the V-plot from the two Cholrapid studies (Figure 4.5). 
Despite marked differences in the distribution of cholesterol values and very 
different diagnostic accuracies, the V-plots from the two studies are almost 
identical. This can be interpreted as the two studies showing the same degree of 
classification agreement between Cholrapid and Cholgold across the spectrum of 
cholesterol values. Figure 4.6 explains in details the steps for the calculation of 
the V-plot and the application of the V-test accuracy in a sample. 
 
4.6 Application of the V-test to any population 
Once the V-plot has been established for the relationship between any two 
indices, the overall agreement between them can be projected to any other 
distribution of severity. For example, once a V-plot is derived from either of the 
two Cholrapid studies, it is possible to calculate the classification agreement 
between Cholrapid and Cholgold for a specialised outpatient lipid clinic, which is 
mainly formed by very high cholesterol levels (Figure 4.7). Ability to infer 
properties for a new cohort is clinically valuable because clinicians often need to 
use tests in cohorts whose distributions are very different from those in which 
major studies have been conducted.  
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The mathematical approach to the V-test calculation is described in Figure 4.6.  
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4.7 Conclusions 
For any given clinical test being compared with a gold standard, there is no 
universal value of diagnostic accuracy. It will always vary progressively from 
almost 100% at the extremes (of health and disease) to approximately 50% 
(close to pure chance) near the diagnostic cut-point. The make-up of the sample 
of patients being studied (extremes versus intermediate) can therefore 
completely control the obtained value for diagnostic accuracy. This means that 
reports of diagnostic accuracy in isolation are an unsafe basis to evaluate a 
clinical test. Sensitivity, specificity, predictive values and ROC curves are just as 
controllable by the make-up of patient sample.  
Authors and readers should therefore focus on whether a studied sample is 
particularly rich in extreme patients or intermediate patients.     
The V-test approach described here exposes the variation of diagnostic accuracy 
along the spectrum of disease and makes it easy to use classification agreement 
drawn from one distribution of patients (v-plot) to derive the expected diagnostic 
accuracy for any other distribution of interest.   
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4.8 Figures 
 
 
    
 
 
 
 
 
  
   
 
 
 
  
        
 
 
  
Figure 4.1: Disease severity and classification agreement between methods 
Schematic representation of the principle that classification agreement between two 
methods of measurement vary across the range of disease severity. At the extremes of 
disease and health agreement is 100%. Close to the classification cut-off, around the 
intermediate range of disease severity, agreement falls, reaching a nadir which can be as 
lower as 50%.   
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Figure 4.2: Diagnostic performance of the new cholesterol test 
The performance of the new cholesterol test (Chol rapid) changed significantly between the two studies. The 
overall accuracy of Chol rapid to diagnose hypercholesterolaemia fell in the primary care retrospective cohort (B), 
when compared to the initial validation study (A). Values of area under ROC curve, sensitivity, specificity and 
predictive values were also largely different.   
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Figure 4.3: Measurement agreement between Chol rapid and Cho gold is equal between studies 
Despite different magnitudes of classification agreement (diagnostic accuracy) between Chol rapid and Chol gold in the two studies, the raw 
measurement disagreement between the two methods remained unchanged. This can be appreciated from the vertical scatter of plot A and from 
Bland-Altman plots (B). It can be inferred that the observed drop in Chol rapid performance in the primary care study cannot be explained by a 
change in its true measurement performance.     
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Figure 4.4: Histogram of cholesterol values from both studies 
Whilst the validation study included patients with a wide range of cholesterol values, the 
primary care cohort was formed predominantly of patients with intermediate values of 
cholesterol.  This difference was responsible for the significant drop in Chol rapid accuracy 
reported in the primary care study. 
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Figure 4.5: The V-plot agreement between Chol rapid and Chol gold 
The V-plot permits a visual demonstration that the classification agreement between 
Chol rapid and Chol gold is equal in the two studies, in each quantile of disease severity. 
The overall classification agreement (diagnostic accuracy of Chol rapid) could change 
between studies, depending on the proportion of patients in each quantile.     
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Figure 4.6: V-test methodology explained   
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 Figure 4.7: Calculating the overall accuracy in different samples using the V-plot 
The V-plot agreement between Chol rapid and Chol gold can be derived from any study which compared the two methods 
(top panel). It can be used as a fingerprint of classification agreement to calculate the overall agreement between Chol 
rapid and Chol gold in any sample in which the distribution of cholesterol values is known (samples A, B and C).    
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5 Hybrid iFR-FFR decision-making strategy: 
implications for enhancing universal 
adoption of physiology-guided coronary 
revascularisation 
  
91 
 
5.1 Introduction 
Despite the evidence demonstrating the benefits of coronary revascularisation 
guided by fractional flow reserve (FFR)13-15, its adoption into widespread clinical 
practice remains low; estimated as 6-8% worldwide33, 60.  The reasons for this are 
multi-factorial33, including incomplete reimbursement, lack of widespread easy 
access to vasodilator drugs and challenges associated with technicalities of the 
procedure.  
The need for vasodilator administration for FFR calculation is perhaps a common 
contributor to all these factors. Therefore, a diagnostic strategy which decreases 
the proportion of patients which needs vasodilator administration could 
potentially simplify assessment and reduce procedural time and costs. Such an 
approach would have the potential to bring physiology-guided revascularisation 
to many more patients, thereby improving clinical outcomes and improving 
healthcare cost-efficiency61.      
The instantaneous wave-Free Ratio (iFR) is a novel pressure-only invasive index 
of coronary stenosis severity which does not require the administration of 
vasodilator drugs, such as adenosine38. Like FFR, iFR uses only pressure and is 
performed with a standard coronary pressure guide wire. However, in contrast to 
FFR, iFR is calculated at rest, without pharmacological provocation. Recent 
studies which directly compared the classification of intermediate coronary 
stenoses by iFR and FFR38, 49 revealed a consistent pattern of agreement 
between the two methods: 1) outside of the intermediate range of iFR and FFR 
values agreement is very high (> 90%), whilst 2) disagreements are of small 
magnitude and concentrated in the zone near their cut-offs58. Trials with clinical 
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endpoints will evaluate whether these small disagreements in the uncertain zone 
around the current FFR cut-off affect patient outcome.  
Meanwhile, the high classification agreement between FFR and iFR outside of 
the intermediate zone may provide the opportunity for a staged, hybrid iFR-FFR 
decision-making strategy, in which only patients within a certain range of 
intermediate iFR values would require adenosine for FFR classification of 
lesions. This hybrid iFR-FFR strategy might achieve a high classification 
agreement with an FFR-only approach (and thus continue to deliver an FFR-
based classification of lesions), whilst significantly reducing the number of 
patients who require vasodilator administration. 
In this study, we sought to evaluate the proportion of patients in clinical practice 
which could be free from vasodilator administration in a hybrid iFR-FFR decision-
making strategy of revascularisation whilst matching the stenoses classification 
of an FFR-only strategy.   
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5.2 Methods  
5.2.1 Patient population  
This study evaluated 577 coronary stenoses from 550 patients in which iFR and 
FFR was compared. Studies and centres contributing data were: the European 
ADVISE Registry study population (Hospital Clínico San Carlos in Madrid, Spain; 
Guy’s and St Thomas’ NHS Foundation Trust, London; and the Academic Health 
Science System of Imperial College London, UK; N=339)58; and an independent 
South Korean study (Seoul National University Hospital and Keimyung University 
Dongsan Medical Center; N=238)49.  
 
5.2.2 Haemodynamic data collection and analysis  
Acquisition of physiological data for FFR calculation was performed according to 
conventional practice42 using commercially available FFR systems (RadiView 
console and PressureWire Certus, St. Jude Medical, Minneapolis, Minnesota; 
and Combomap console and Prestige pressure guide wire, Volcano Corporation, 
San Diego, California).  In the European cohort (N=339), intravenous adenosine 
was used for the calculation of FFR in 98% of the cases, administered via a 
central line, with doses ranging from 140mcg/Kg/min to 200mcg/Kg/min; in the 
remaining 2% of the cases the intra-coronary route was used. In the South 
Korean cohort, both intravenous and intracoronary routes were used in each 
patient (140mcg/Kg/min intravenously and 40mcg - 80mcg for intracoronary), 
and the lowest value of FFR was chosen for analysis.  Digital data was extracted 
from FFR console platforms and processed off-line in a core laboratory 
(International Centre for Circulatory Health, National Heart and Lung Institute, 
UK) using a custom software package with Matlab (Mathworks, Inc., Natick, 
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Massachusetts). Each iFR trace was evaluated blinded from its FFR counterpart. 
iFR was calculated using fully automated algorithms applied to time-aligned 
pressure traces over the wave-free period of diastole over a minimum of 5 beats, 
before adenosine administration, as previously described38. iFR is defined as the 
ratio of distal coronary pressure to proximal coronary pressure during the wave-
Free period in diastole. Resting Pd/Pa was calculated from baseline traces, as 
the ratio of mean distal (Pd) to proximal (Pa) coronary pressures, over the entire 
cardiac cycle. 
 
5.2.3 Comparison between hybrid iFR-FFR strategy and FFR-only strategy  
This study retrospectively compared two possible strategies to guide coronary 
revascularisation:  
 
Strategy 1: FFR-only strategy: This strategy was used as the reference. All 
interrogated stenoses received adenosine for FFR calculation and all decisions 
were based on the final FFR result using the currently recommended 0.8 cut-off 
value. No decision was taken based on the iFR result. 
 
Strategy 2: Hybrid iFR-FFR strategy: A series of two independent iFR values 
were identified: one with a high negative predictive value (exceeding 90%) to 
exclude FFR-significant stenoses (defer iFR value) and another with a high 
positive predictive value (exceeding 90%) to identify FFR-significant stenoses 
(treatment iFR value). A positive result was defined as FFR or iFR ≤ 0.8 and it 
was assumed that only stenoses with iFR values between the defer and 
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treatment iFR values would have been given adenosine and followed standard 
FFR classification of lesions (Figure 5.1).   
 
5.2.4 Endpoints for comparison between FFR-only and hybrid iFR-FFR 
strategies    
This study used the following endpoints to compare the two strategies:  
 
Overall classification agreement between strategies: Give its proven safety 
as a guide to revascularisation, the classification of stenoses by the FFR-only 
strategy was used as the reference. The overall classification agreement (when 
both strategies classified a stenosis as significant or not significant) between the 
iFR-FFR strategy and the FFR-only strategy was calculated. An overall 
agreement of 95% was considered ideal.    
Proportion of patients adenosine-free: In the hybrid iFR-FFR strategy, the 
proportion of stenoses which fell outside the adenosine requirement zone (which 
would be free from adenosine in a hybrid iFR-FFR strategy) was calculated for 
each level of overall agreement with the FFR-only strategy. For comparison, in 
the FFR-only strategy, all interrogated stenoses (100%) required adenosine 
administration. In the hybrid iFR-FFR strategy, the size of the zone between the 
defer and treatment iFR values was calculated (in 0.01 iFR units). This zone 
represented the iFR values within which administration of adenosine was 
required for FFR calculation.  
 
5.2.5 Comparison with a hybrid Pd/Pa-FFR strategy 
The same methodology was then applied for the evaluation of a Pd/Pa-FFR 
hybrid strategy. The proportion of vessels which would be free from adenosine 
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with a hybrid Pd/Pa-FFR strategy was compared to the iFR-FFR strategy, for 
each level of agreement with the FFR-only strategy.  
 
5.2.6 Statistical analysis 
Statistical calculations were performed using Matlab (Mathworks, Inc.). Data 
were expressed as mean ± standard deviation for continuous variables and 
percentages for categorical variables.  
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5.3 Results 
 
5.3.1 Population characteristics 
Patient demographics and stenosis characteristics are summarised in Table 5-1. 
The majority of stenoses were physiologically intermediate, representative of 
patients undergoing FFR assessment of intermediate lesions in daily clinical 
practice. Mean FFR was 0.81 ± 0.10; 80% of stenoses had FFR between 0.6 and 
0.9; and only 13% had FFR ≤ 0.7 (Figure 5.2).   
 
5.3.2 Overall classification agreement between hybrid iFR-FFR strategy and FFR-
only strategy  
Using a deferral iFR value of > 0.93, a treatment iFR value of < 0.86 and with 
adenosine only given to stenoses with iFR values between 0.86 and 0.93, 
resulted in an overall 95% agreement with the FFR-only strategy (Figure 5.3). A 
deferral value of iFR > 0.93 demonstrated a negative predictive value of 91% to 
exclude FFR-significant stenoses and a treatment iFR value of < 0.86 had a 
positive predictive value of 92% to identify FFR-significant stenoses.  
 
5.3.3 Reduction in adenosine requirement with hybrid iFR-FFR strategy 
The utilisation of a hybrid iFR-FFR strategy would have significantly reduced the 
number of patients in whom adenosine was required. For an overall classification 
agreement of 95% with the FFR-only (adenosine-to-all) strategy, in the hybrid 
iFR-FFR strategy 57% of the stenoses would have become adenosine-free 
(Figure 5.3 and Figure 5.4). For a classification agreement between the 
strategies of 85% and 90%, respectively, the stenosis population predicted to be 
free of adenosine was 88% and 74% respectively (Figure 5.4 and Figure 5.5).  
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5.3.4 Size of adenosine requirement zone    
For a hybrid iFR-FFR strategy with a 95% classification agreement with the FFR-
only strategy the width of the adenosine requirement zone was 0.08 iFR points 
(from 0.86 to 0.93), which represented 43% of this study population. The larger 
the adenosine requirement zone, the higher the overall agreement between a 
hybrid iFR-FFR strategy and the FFR-only strategy. However, increasing the 
adenosine zone also decreased the proportion of stenoses which became 
adenosine-free (Figure 5.5). 
 
5.3.5 Incremental benefits of a hybrid iFR-FFR strategy compared to a hybrid 
PdPa-FFR strategy 
iFR is superior to PdPa when used in a staged approach with FFR. For the same 
level of agreement with the FFR-only strategy, a hybrid iFR-FFR strategy 
significantly increased the number of adenosine-free patients when compared to 
a hybrid PdPa-FFR strategy. For magnitudes of agreement of 90%, 96%, 
respectively, the proportion of adenosine-free patients gained with iFR (over 
Pd/Pa) was 21%, and 28% (Figure 5.6).  
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5.4 Discussion 
Whilst we await for clinical trials which evaluate the safety of iFR as an 
independent tool to guide to coronary revascularisation, this study shows that a 
hybrid decision-making strategy of coronary revascularisation with iFR and FFR 
has the potential to foster adoption of physiology-guided PCI. Our results 
demonstrate that such an approach has the potential to drastically reduce the 
need for adenosine administration whilst maintaining a 95% classification 
agreement with an FFR-only strategy.   
 
5.4.1 Implications to increased adoption of physiology-guided PCI   
Adding to the evidence already provided by the DEFER and FAME trials14, 15, 27, 
the FAME II study recently demonstrated that, when compared to medical 
therapy alone, percutaneous coronary intervention (PCI) can reduce coronary 
events, when flow limiting lesions are identified by FFR13. It is therefore 
unfortunate that currently 92 to 94% of all coronary interventions worldwide are 
performed without any invasive physiological guidance3, 33, 60, and it is clearly in 
the patients’ interest to make physiology-guided PCI available to all. As the need 
for the administration of adenosine is one of the impediments to FFR utilisation30, 
33, 62, 63, a hybrid strategy with iFR could potentially facilitate the application of 
pressure wire interrogation, decrease procedural time62, costs61, avoid the small 
risks associated with central venous access and adenosine administration and 
minimise patient inconvenience.  Also, as the need for a femoral venous sheath 
would be avoided in the majority of patients, a hybrid iFR-FFR strategy could 
potentially increase the number of radial procedures, which is in itself associated 
with improved outcomes64. Our results, therefore, suggest that a hybrid 
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revascularisation strategy with iFR and FFR has the potential to significantly 
increase adoption of physiology-guided PCI in clinical practice, by combining iFR 
and FFR in the same diagnostic pathway (Figure 5.3).      
 
5.4.2 Adenosine-free population depends on desired agreement with FFR   
The desired magnitude of agreement between a hybrid iFR-FFR strategy and an 
FFR-only strategy will determine the proportion of adenosine-free patients in any 
given population and the iFR values chosen to make deferral or treatment 
decisions (Figure 5.4).    
If limits of iFR were chosen to achieve an overall 95% agreement with FFR we 
found that this would free 57% of patients from adenosine during physiological 
assessment in the catheterization laboratory. We believe this represents a safe 
and clinically meaningful balance between classification match and potential for 
increase adoption of physiology-guided procedures. However, If a 90% overall 
match with an FFR-only strategy was to be accepted, the proportion of patients 
free from adenosine would increase to 74%, with iFR values to defer and treat of 
< 0.89 and > 0.92, respectively (adenosine would be required when iFR falls 
between 0.89 and 0.92). Finally, if clinicians were only happy to accept a 99% 
agreement between strategies, 31% of patients would still be spared from 
administration of adenosine if iFR and FFR were used in a staged approach 
(Figure 5.4 and Figure 5.5). 
 
5.4.3 Clinically representative study population 
The results of our study are relevant to the daily clinical application of 
physiological interrogation of angiographic intermediate stenoses, as our sample 
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was formed by two independent populations of patients undergoing clinical FFR 
measurement from sites in Europe and Asia49, 58. Importantly, patients in this 
sample were not specifically recruited for a research study, and therefore reflect 
the daily clinical practice of physiological interrogation of angiographically 
intermediate coronary stenoses.  Because the majority of our patients had 
physiologically intermediate stenoses straddling the FFR treatment cut-off (mean 
FFR of 0.81, with 80% of FFR values falling between 0.6 and 0.9), 43% of them 
would still have to receive adenosine for a 95% agreement with an FFR-only 
strategy. It is likely that in other study populations, which included patients with 
more severe lesions (away from the intermediate range) even more patients 
would be free of adenosine for the same magnitude of agreement with an FFR-
only strategy.  
For instance, if we apply the same hybrid iFR-FFR strategy to the ADVISE study 
population38 (which had mean FFR of 0.72 ± 0.2, with only 41% of stenoses 
between 0.7 and 0.9), using the same iFR values to defer and treat stenoses (> 
0.93 and < 0.86, respectively) we would obtain a similar classification match with 
an FFR only strategy (96%). However, the proportion of adenosine-free patients 
would significantly increase to 77%.  
This example demonstrates that, in populations which include more patients with 
physiologically severe stenoses, such as the ones encountered in the DEFER15 
(mean FFR 0.73), FAME14 (mean FFR 0.71) and FAME II13 (mean FFR 0.68) 
studies, the application of a hybrid iFR-FFR strategy is likely to free a 
proportionally higher percentage of patients from adenosine.  
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5.4.4 Allowing for an FFR 0.75 – 0.8 grey zone 
The analysis presented in this study was performed using a fixed FFR cut-off of 
0.8, as mandated by current clinical guidelines3, 42 as a result of the FAME14 and 
FAME II13 studies. However, the DEFER trial15 and, more importantly, its 5 years 
follow up results27, left little doubt about the safety of deferring stenosis with FFR 
≥ 0.75. This overlap between FAME and DEFER FFR cut-offs is the widely 
acknowledged 0.75 - 0.8 FFR grey zone65, within which it is both mandated to 
treat, and known to be safe to defer, coronary lesions.  
Therefore, if clinicians opt to use a hybrid iFR-FFR strategy which accounts for 
this FFR grey zone, the number of patients free of adenosine would increase to 
76% (Figure 5.7). For this purpose, an iFR value of > 0.90 could be used to defer 
revascularisation in stenoses (with 94% negative predictive value to exclude 
stenoses with FFR < 0.75), whilst an iFR value of < 0.86 would be used to treat 
stenoses (with a 93% positive predictive value to identify stenoses with FFR ≤ 
0.8).      
A summary of the results is presented in Figure 5.8. 
 
5.4.5 Disagreement between strategies is infrequent and of small magnitude 
The overall 95% agreement between the hybrid iFR-FFR strategy and the FFR-
only strategy in practice means that only 1 in 20 stenosis would have a different 
classification with the two approaches. Although this number is small (95% 
agreement between test modalities being unusual in clinical practice), it is still 
clinically relevant to understand the magnitude of such disagreement, when it 
occurs.   
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At the upper range of iFR values (negative iFR), disagreements only represented 
3.1% of the overall population (18 out of 577 cases). Out of those cases, 67% 
(12) fell within the FFR grey zone of 0.75 - 0.8 and only in 3 cases FFR was < 
0.7. At the lower range of iFR results (positive iFR), disagreements represented 
only 1.7% of the overall population. Out of those cases, in 60% FFR fell between 
0.8 and 0.85, and only 1 above 0.88. 
Therefore, given the small magnitude of disagreement between strategies 
compared with the range of uncertainty within trial-based FFR-guided 
management itself, it might be speculated that classification of the small number 
of lesions differently by the hybrid iFR-FFR strategy from the FFR-to-all strategy, 
will not have a significant effect on the risk of cardiac events. The scope for such 
small disagreements would need to be taken in the context of the opportunity for 
bringing rapid, symptom-free physiological targeting of PCI to a significantly 
higher number of patients with coronary disease.  
The relationship between iFR and FFR across different study populations reveals 
that the majority of differences in stenosis classification occur close to the iFR 
and FFR cut points, which could potentially have little or no effect on patient 
outcome58. However, prior to the application of a single dichotomous iFR cut 
point and implementation of iFR into clinical practice as an independent method 
to guide coronary revascularisation, clinical studies are warranted to demonstrate 
the safety and efficacy of iFR. Until such studies clarify the usefulness of iFR as 
an independent diagnostic modality, a hybrid iFR-FFR strategy provides a 
pragmatic strategy to increase adoption of physiology-guided revascularisation in 
the catheter laboratories. 
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5.5 Limitations 
This study was a retrospective analysis performed on data collected from two 
clinical cohorts of patients who underwent FFR evaluation, using different doses 
and routes for adenosine administration. The proposed hybrid iFR-FFR 
revascularisation strategy was not tested prospectively against clinical outcomes. 
The positive side of this real-world, retrospective analysis is that our proposed 
FFR-only strategy (with varying doses of adenosine) reflects the clinical practice 
of interventionists in catheterisation laboratories across centres in Europe and 
Asia." 
The comparison between the classification of coronary stenoses by the two 
revascularisation strategies was made without an independent discriminator, 
such as a non invasive perfusion modality or invasive coronary flow. Therefore, 
when strategies disagreed in classifying a lesion as significant / non-significant, it 
is not possible to infer which of them correctly identified or excluded flow limiting 
lesions.    
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5.6 Conclusions 
Whilst we await the results of clinical trials which evaluate efficacy of iFR as a 
sole method to guide coronary revascularisation, a hybrid decision-making 
revascularisation strategy guided by iFR and FFR could drastically reduce the 
need for adenosine administration in clinical practice and maintain a high 
diagnostic agreement (≥ 95%) with FFR classification of stenoses. Therefore, the 
adoption of a hybrid iFR-FFR approach could expand the utilisation of 
physiology-guided revascularisation in clinical practice and improve patient 
outcome.  
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5.7 Tables 
 
 
 
 
 
 
    
 
 
  
SD= Standard deviation of the difference 
ADVISE Registry study 339 (59%)
South Korean study 238 (41%)
62 ± 8
422 (73%)
343 (59%)
171 (30%)
385 (67%)
37 (6%)
414 (72%)
50.2 ± 13
Left anterior descending artery lesions, n (%)
Diameter stenosis (%)
Male, n (%)
Hypertension, n (%)
Chronic kidney disease, n (%) 
Population from, n (%)
Age, yrs ± SD
Diabetes mellitus, n (%)
Dyslipidemia, n (%)
Table 5-1: Patient demographic data 
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5.8 Figures 
 
 
 
  
      
 
 
 
 
 
 
 
 
 
 
  
Study methodology
Strategies for coronary revascularisation in a clinical population of intermediate stenoses 
(N=577)  
Strategy 1
FFR - only strategy
FFR ≤ 0.8
TREAT
FFR > 0.8
DEFER
Adenosine to all
Give adenosine
FFR ≤ 0.8
TREAT
FFR > 0.8
DEFER
iFR < treat value
TREAT
iFR 
Between treat and 
defer values
iFR > defer value
DEFER
Strategy 2
Hybrid iFR- FFR strategy
Study hypothesis
A Hybrid iFR-FFR strategy of revascularisation would reduce adenosine requirement in clinical practice, 
whilst maintaining a high classification agreement with the FFR-only strategy
Figure 5.1: Study methodology flowchart and study hypothesis 
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Figure 5.2: Frequency histogram of study population 
Distribution of FFR values. The majority of lesions were classified as 
physiologically intermediate, with mean FFR 0.81 ± 0.1 and 80% of FFR values 
between 0.6 and 0.9.   
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Figure 5.3: Hybrid revascularisation strategy with instantaneous wave-Free Ratio (iFR) and fractional flow reserve 
reduces the adenosine requirement in clinical practice 
Coronary revascularisation decisions can be made without adenosine when iFR is < 0.86 (positive predictive value of 92%) 
or when iFR is > 0.93 (negative predictive value of 91%). In clinical practice, such iFR-based decisions can be made in 
57% of patients. When iFR values fall between 0.86 and 0.93, adenosine is given and the FFR cut-off of 0.8 is used to 
guide revascularisation.  This hybrid iFR-FFR approach has a 95% classification agreement with an FFR-only, adenosine-
to-all, strategy.  Green dots represent the agreement between iFR and FFR and red dots show disagreement points. Grey 
dots inside the grey zone represent the stenoses which will be classified by FFR, following adenosine administration.    
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Desired agreement with FFR-only (adenosine-to-all) strategy
Deferral iFR value: > 0.96
Treatment iFR value: < 0.82
Adenosine zone: 0.82 – 0.96
Deferral iFR value: > 0.93
Treatment iFR value: < 0.86
Adenosine zone: 0.86 – 0.93
Deferral iFR value: > 0.92
Treatment iFR value: < 0.89
Adenosine zone: 0.89 – 0.92
Deferral iFR value: > 0.91
Treatment iFR value: < 0.90
Adenosine zone: 0.9 – 0.91
Figure 5.4: Hybrid iFR–FFR strategy reduces the number of patients requiring adenosine for any desired 
agreement with an FFR-only strategy 
Using a hybrid iFR-FFR approach can reduce adenosine requirement in clinical practice by 74% with a 90% 
agreement with an FFR-only, adenosine-to-all, approach. For 95% and 99% agreement, the reduction in 
adenosine requirement would be 57% and 31%, respectively.    
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90% overall agreement
Adenosine-free population: 74%
Deferral iFR value: > 0.92 / Treatment iFR value: < 0.89
95% overall agreement
Adenosine-free population: 57%
Deferral iFR value: > 0.93 / Treatment iFR value: < 0.86
Figure 5.5: Population free from adenosine and the overall agreement with an 
FFR-only strategy depends on the size of the adenosine requirement zone 
 If adenosine is given to a larger window of iFR values, the diagnostic agreement with 
a FFR-only strategy increases (lower panel), albeit at a cost of less patients being free 
from adenosine (upper panel). 
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Figure 5.6: Incremental adenosine-saving benefits of iFR over resting PdPa 
For each level of agreement with an FFR-only strategy, the utilisation of a hybrid 
iFR-FFR strategy significantly increases the adenosine-free population, when 
compared to a hybrid PdPa-FFR strategy.  The absolute number of patients saved 
with each strategy is shown in top panel, with the incremental benefit of iFR over 
PdPa demonstrated in bottom panel.    
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Figure 5.7: Adenosine-free population increases if FFR grey zone is 
accounted for 
If the widely acknowledged FFR 0.75 – 0.8 diagnostic grey zone is accounted 
for, the proportion of patients free of adenosine in a hybrid iFR-FFR strategy 
would increase to 76%. In this scenario, a deferral iFR value of > 0.90 could be 
used with a negative predictive value of 94%, maintaining an overall agreement 
with FFR-only strategy of 95%. 
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FFR - only strategy 
All patients require 
adenosine
Reference strategy
FFR ≤ 0.8
TREAT
FFR > 0.8
DEFER
Adenosine to all
N = 577
Adenosine
N = 249
Adenosine-free patients                    
57% (N = 328)
Agreement with FFR-only strategy 
95% (N = 549)
FFR ≤ 0.8
TREAT
FFR > 0.8
DEFER
iFR < 0.86
TREAT
(N= 130)
iFR > 0.93
DEFER
(N= 198)
iFR 
[0.86 - 0.93]
Hybrid iFR - FFR strategy 
Study results
Strategies for coronary revascularisation in a clinical population of intermediate stenoses 
(N=577)  
Figure 5.8: Summary of the predicted results of a hybrid decision-making 
revascularisation strategy with instantaneous wave-Free Ratio (iFR) and fractional 
flow reserve (FFR). 
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6 The baseline instantaneous wave-free ratio 
as a pressure-only estimation of underlying 
coronary flow reserve   
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6.1 Introduction  
Three decades of research have repeatedly demonstrated the diagnostic and 
prognostic values of coronary flow reserve (CFR) in patients with coronary artery 
disease (CAD). Whether measured invasively or non-invasively, CFR has been 
shown to be able to identify patients with myocardial blood flow impairment, 
predict prognosis and stratify which lesions may benefit from revascularisation9, 
32, 66-70.  
In the cardiac catheterisation laboratory, however, CFR has largely been 
replaced by a pressure-only measurement, fractional flow reserve (FFR), as the 
most common invasive tool to guide coronary revascularisation. FFR uses a ratio 
between distal coronary and aortic pressures under conditions of maximal 
hyperaemia42 to estimate the relative flow reduction caused by a stenosis. The 
development of pressure-only FFR has undoubtedly facilitated the clinical 
application of invasive physiology and its role as a decision-making tool is 
supported by large clinical trials13-15. There remain, however, 30% of cases in 
which information derived from pressure FFR conflicts with direct measurement 
of underlying coronary flow reserve (CFR)35-37. These diagnostic disagreements 
are known not to be a result of measurement error but instead represent true 
biological differences between CFR and FFR: because both indices rely on the 
achievement of maximal coronary flow for their calculation, for any given stenosis 
their values move in opposite directions when hyperaemic flow increases35, 36 
(Figure 6.1).     
The instantaneous wave-free ratio (iFR) has recently been proposed as an index 
which uses pressure-only recordings to identify physiologically significant 
stenoses38. Because iFR does not intend to estimate maximal myocardial blood 
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flow with pressure, it differs from FFR as it does not require pharmacological 
induction of hyperaemia for its calculation.  Although early studies have reported 
a close relationship between iFR and FFR38, 39, 58, 71, it is not known which 
pressure-only index agrees more closely with the true flow reserve CFR.  
In this study we performed the first comparison between pressure indices iFR 
and FFR against coronary flow velocity reserve (CFVR) in patients undergoing 
invasive functional assessment of coronary artery disease. We sought to 
evaluate whether iFR, by avoiding hyperaemia, would agree more closely with 
underlying CFVR.  If confirmed, this would provide further physiological validation 
for iFR as a vasodilator-free index of coronary disease severity. 
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6.2 Methods 
 
6.2.1 Study sample  
This study included 216 stenoses from 186 patients scheduled for coronary 
angiography or percutaneous coronary intervention at the Academic Medical 
Centre, Amsterdam, the Netherlands, and Imperial College, London, United 
Kingdom. The sample from Amsterdam included 141 stenoses from two sub-
studies: one sub-sample of 56 lesions in which pressure and flow was measured 
simultaneously, collected between November 2001 and January 2012. The other 
includes 85 stenoses with non-simultaneous measurements of pressure and 
flow, from the BSR study dataset51, with data collected from April 1997 and 
September 2006. The sample from Imperial College consisted of 75 stenoses, all 
collected from 2010 to 2013, as part of the ADVISE study and subsequent 
studies from the group. Exclusion criteria were restricted to significant valvular 
pathology and prior coronary artery bypass graft surgery. The local ethical review 
boards approved the respective study protocols, and all subjects gave written 
informed consent. 
 
6.2.2 Cardiac catheterization and hemodynamic recording 
Cardiac catheterization was performed according to standard practice. 5000iu 
unfractionated intravenous heparin was given at the start of the procedure 
together with 300mcg-600mcg of intracoronary GTN Invasive physiological data 
was acquired after diagnostic angiography. In 131 stenoses pressure and flow 
velocity were measured simultaneously with a 0.014inch combined pressure and 
Doppler sensor-tipped wire (ComboWire® XT, Volcano Corporation, San Diego, 
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CA). In the remaining 85 lesions pressure and flow were measured sequentially 
with separate pressure and flow wires. Distal and proximal pressures were 
normalised at the tip of the catheter. Measurements were performed during 
baseline conditions and during hyperaemia, induced by either intravenous 
infusion in 75 cases (140µg/kg/min), or intracoronary bolus injection (20-60µg) of 
adenosine in the remaining 141 stenoses.  
 
6.2.3 Hemodynamic data analysis 
Data (EKG, pressure and flow velocity) was extracted from a digital archive 
(ComboMap® or personal computer). Pressure drift was identified either by 
returning the pressure sensor to the catheter tip at the end of the procedure or by 
means of pressure drop-flow velocity curves, using the zero-flow pressure 
intercept as a measure of drift. Hemodynamic data analysis was performed off-
line using a custom software package in MatLab (Mathworks Inc., Natick, Mass). 
Pressure and flow data acquired simultaneously were aligned as previously 
described72. The diastolic iFR window was identified using fully automated 
algorithms acting over EKG-gated, time-aligned pressure traces, as described 
previously38. Quantitative coronary angiography (QCA) was performed off-line in 
appropriate consoles. 
 
6.2.4 Definition of physiological indices  
Pa = Proximal (aortic) pressure (mmHg) 
Pd = Distal (coronary) pressure (mmHg) 
Fractional Flow Reserve (FFR) = 
  
  
 at whole-cycle hyperaemia 
Instantaneous wave-Free Ratio (iFR) = 
  
  
 at baseline iFR window 
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Instantaneous wave-Free Ratio during adenosine administration (iFRa) = 
  
  
 at hyperaemic iFR 
window 
Baseline Flow = Mean baseline whole-cycle coronary flow velocity (cm/s) 
Flow FFR = Mean whole-cycle coronary flow velocity at stable hyperaemia (cm/s) 
Flow iFR = Mean coronary flow velocity during the baseline iFR window (mid-diastole) (cm/s)*  
Coronary flow velocity reserve (CFVR) ** = 
                                    
                                  
  
Hyperaemic Stenosis Resistance (HSR) = 
                                               
                                      
  
 
 
  
* Only calculated in stenoses in which pressure and flow velocity were measured simultaneously (N=131). 
** Coronary flow velocity reserve (CFVR) refers to indices using a ratio of flow velocities (invasive Doppler 
and non-invasive stress echocardiography) and coronary flow reserve (CFR) refers to measures of 
underlying flow rate (Positron Emission Tomography and invasive thermo-dilution).  
 
6.2.5 Statistical Analysis 
Statistical analysis was performed using Stata 13.1, (Statacorp, USA).  Data are 
expressed as mean ± standard deviation (SD), unless stated otherwise. 
Correlations between pressure-only indices and CFVR were assessed by 
calculation of the Pearson’s correlation coefficient rho (ρ) by Greiner’s relation 
using the somersd routine in Stata, since this is more robust to outliers and can 
take account of clustering of data within patients73. Receiver-operating-
characteristics (ROC) curves were constructed for each pressure-only index 
against CFVR as the reference standard, using multiple CFVR cut-offs (1.7, 2.0, 
2.5 and 3.0).  The areas under the ROC curve (ROCAUC) were compared using 
somersd to calculate Harrel’s c. An additional comparison of ROC curves was 
made with the comproc routine in Stata which uses percentile values derived 
from the empirical distribution of the test measure among controls with a 
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correction for ties and taking account of clustering74. A Wald test for comparisons 
based on bootstrap standard errors (1000 replications) was performed, but as 
this analysis gave almost identical values to somersd these results have not 
been presented below. The classification agreement (and sensitivity, specificity, 
negative predictive value and positive predictive value) between pressure only 
indices (iFR and FFR) and CFVR was calculated using ROC-derived cut-offs 
(highest sum of sensitivity and specificity for a CFVR of 2.0) and using clinically 
established cut-offs  (CFVR 2.067; FFR 0.8013, 14; and the equivalent iFR cut-off 
of 0.9075). When evaluating the underlying haemodynamics of large baseline-
hyperaemic pressure disagreements, we used an FFR cut-off of 0.75 for 
significance, as this has been demonstrated to be the optimal ischaemic FFR 
cut-off across multiple studies25, 76. Comparison of means was performed using 
Student’s t-test. A p value of < 0.05 was considered statistically significant. 
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6.3 Results 
 
6.3.1 Sample characteristics  
The 216 stenoses (186 patients) demonstrated unimodally distributed iFR, FFR 
and CFVR values. Mean FFR was 0.74 ± 0.17, mean iFR was 0.81 ± 0.21 and 
mean CFVR was 2.1 ± 0.77. Mean diameter stenosis was 56 ± 16%. The 
majority of patients included in this study presented with stable symptoms (98%), 
with 52% demonstrating single-vessel disease. 56% of all stenoses evaluated 
were in the left anterior descending (LAD) coronary artery. Angiographic and 
demographic characteristics are summarised in Table 6-1.  
 
6.3.2 Diagnostic agreement between pressure-only indices and CFVR  
iFR showed a stronger correlation with underlying CFVR (iFR-CFVR ρ=0.68 
[0.60, 0.76]) than did FFR (FFR-CFVR ρ=0.50 [0.39, 0.62]) (p<0.001 for 
comparison). Across the entire range of functional stenosis severities, iFR was 
found to be in closer diagnostic agreement with CFVR than FFR (iFR ROCAUC 
0.82 [CI 0.76 – 0.88] versus FFR ROCAUC 0.72 [CI 0.65 – 0.79], p < 0.001, for a 
CFVR of 2) (Figure 6.2). This was particularly evident within the intermediate 
0.60 - 0.90 FFR range (iFR ROCAUC 0.78 [CI 0.69 – 0.86] versus FFR ROCAUC 
0.59 [CI 0.48 – 0.69], p < 0.001, for a CFVR of 2). iFR also demonstrated better 
diagnostic discrimination over baseline Pd/Pa (Pd/Pa ROCAUC 0.78 [0.72 - 0.85], 
p=0.004). The better agreement of iFR with CFVR was found for different CFVR 
cut-offs (Table 6-2). The iFR cut-off value with the highest diagnostic accuracy to 
identify stenosis with a CFVR < 2 was 0.85. Although iFR values were 
significantly lower when measured at hyperaemia (iFRa) (mean iFRa 0.63 ± 0.22 
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versus mean iFR 0.81 ± 0.21 and mean FFR 0.74 ± 0.17, p<0.001), the 
agreement between iFRa and CFVR was significantly worse than baseline iFR 
(iFR ROCAUC 0.82 [CI 0.76 – 0.88] versus iFRa ROCAUC 0.74 [CI 0.68 – 0.81], 
p<0.001). 
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6.3.3 Pressure-indices and discrimination between stenoses with normal and 
abnormal CFVR 
Mean CFVR of stenoses with iFR value > 0.9 was 2.51 ± 0.7, whilst mean CFVR 
of stenoses with an iFR ≤ 0.9 was 1.69 ± 0.6 (p<0.001).  A lower iFR value of ≤ 
0.85 identified a subgroup of stenoses with a particularly low CFVR (mean CFVR 
of 1.44 ± 0.44 with a positive predictive value to identify stenoses with CFVR of 
less than 2.0 and 2.5 of 83% and 99%, respectively).  
Diagnostic discrimination was not improved by adenosine administration and 
FFR calculation (Figure 6.3). For instance, amongst stenoses with iFR ≤ 0.9, 
those with FFR > 0.8 still had a mean CFVR < 2. Also, amongst stenoses with 
iFR > 0.9 a low FFR result paradoxically identified lesions with an even higher 
CFVR.  
 
6.3.4 Magnitude of coronary flow velocities during baseline and hyperaemia  
FlowFFR was significantly higher than flowiFR in mild stenoses, when FFR > 0.75 
(mean flowFFR 42.3 ± 22.8 cm/s versus mean flowiFR 26.1 ± 15.5 cm/s, p < 0.001, 
Figure 4).  However, amongst FFR-significant lesions (≤ 0.75), flowiFR and 
flowFFR were not significantly different (mean flowFFR 25.8 ± 13.7 cm/s versus 
mean flowiFR 21.5 ± 11.7 cm/s, p = 0.13, Figure 6.4). Both flowFFR and flowiFR 
were significantly higher than whole-cycle baseline flow (flowPd/Pa) across the 
whole spectrum of FFR values (flowPd/Pa 16.8 ± 8.4 cm/s in lesions with FFR ≤ 
0.75; and flowPd/Pa 19.8 ± 8.4 in lesions with FFR > 0.75, p<0.001 for 
comparisons with iFRflow and FFRflow).  
Magnitudes of hyperaemic flow velocities were not different between 
intracoronary (IC) and intravenous (IV) adenosine administration. Amongst mild 
stenoses (with FFR > 0.8) mean flowFFR IV was 42.5 ± 21.6 cm/s versus mean 
125 
 
flowFFR IC 44.5 ± 21.1 cm/s (p=0.61). Amongst functionally severe stenoses 
(FFR<0.6), mean flowFFR IV was 20.8 ± 11.6 cm/s versus mean flowFFR IC 21.9 ± 
12 cm/s (p=0.82). Amongst intermediate lesions (FFR 0.6-0.9) mean flowFFR IV 
was 38.6 ± 15.3 cm/s versus mean flowFFR IC 39.9 ± 20.1 cm/s (p=0.70). 
6.3.5 Prevalence and mechanisms behind large trans-stenotic gradients only 
present at hyperaemia    
High iFR values (iFR >0.90) which, following adenosine administration, 
demonstrated a significant drop in FFR (FFR ≤ 0.75) were observed only in 4.1% 
of cases (Figure 6.5).  
Amongst stenoses with FFR values ≤ 0.75, the difference between iFR and FFR 
values was primarily driven by the magnitude of trans-stenotic flow velocity, with 
larger numerical differences being associated with significantly higher CFVR 
values (Figure 6.5). Analysis of absolute flow velocities in this subgroup of 
stenoses (FFR ≤ 0.75 and iFR > 0.9) revealed that the high value of CFVR was 
caused by higher than average hyperaemic flow velocities with normal values of 
baseline flow (Table 6-3). Furthermore, the magnitudes of hyperaemic coronary 
flow velocities in this subgroup were similar to the ones observed in unobstructed 
lesions, with FFR > 0.80 (Table 6-3). The underlying flow profile of stenoses with 
large gradients only present during hyperaemia are similar to those of FFR-
negative vessels, with high hyperaemic flow velocity and higher than average 
CFVR. Examples of such cases are presented in Figure 6.  
Therefore, amongst stenoses showing a definite abnormal FFR result (≤ 0.75), 
two distinct groups existed with respect to the underlying CFVR value: those with 
abnormal iFR (≤ 0.9), in which CFVR values were also abnormal and those with 
normal iFR (>0.9), which demonstrated significantly higher hyperaemic flow and 
CFVR values (Table 6-3). 
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6.4 Discussion 
In this study we have found that (1) iFR provides better pressure-derived 
diagnostic agreement with CFVR than FFR; (2) the diagnostic conflicts between 
pressure-only indices and CFVR is at least partly caused by the induction of 
hyperaemia, as iFR loses its better classification agreement with CFVR when 
calculated during adenosine administration (iFRa); (3)  flowFFR is higher than 
flowiFR only in physiologically mild stenoses, when FFR > 0.75 and (4) large 
drops from high iFR values to low FFR values are driven by high CFVR and high 
magnitudes of hyperaemic flow. 
6.4.1 iFR – FFR disagreements: comparison with another flow based index  
The classification agreement between iFR and FFR has already been 
extensively evaluated in over 2000 stenoses38, 49, 58, 75 . Multiple studies 
consistently showed the iFR-FFR classification match to be 80 - 90%; similar to 
the agreement reported between different invasive and non-invasive functional 
tests17, 26, 51, 66, 77-79. However, direct comparisons between iFR and FFR are of 
limited value because when disagreements occur it is not possible to infer which 
index correctly identifies flow-limiting stenoses. Simultaneous iFR and FFR 
comparisons against independent discriminators are essential to assess the 
diagnostic performance of both indices. In the present study, therefore, by 
evaluating iFR and FFR against CFVR, an established and extensively studied 
flow-based index, we provide further evidence to support iFR as an index 
capable of detecting flow-limiting coronary disease (Figure 6.2 and Table 6-2). 
The closer diagnostic agreement between iFR and CFVR was observed for 
different CFVR cut-offs and particularly marked within intermediate FFR values 
(Table 6-2), which suggests our results are not driven by the extremes of disease 
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severity. Our findings are similar to those of the CLARIFY study39 and a study by 
van de Hoef et al.71, both of which found that iFR was non-inferior to FFR to 
detect ischaemia using invasive flow and myocardial perfusion imaging, 
respectively. Also, the present study identified 0.85 as the iFR cut-off with the 
maximal accuracy to identify flow-limiting stenoses by CFVR, value similar to 
0.86 reported in CLARIFY39.      
.   
 
6.4.2 Adenosine does not significantly increase coronary flow in patients with 
obstructive CAD 
Whilst early FFR experiments elegantly demonstrated that hyperaemic flow is 
significantly higher than baseline flow in healthy young animals with normal 
coronary arteries23 and in healthy young human subjects35, we found that 
adenosine does not invariably increase coronary flow in patients with CAD 
(Figure 6.4). Previous studies have indeed suggested that direct extrapolation of 
coronary haemodynamic findings cannot be made from animals or healthy 
subjects to patients with vascular risk factors, coronary artery disease and 
varying degrees of microvascular dysfunction. Uren et al demonstrated with PET 
that in patients with CAD hyperaemic flow is on average only higher than 
baseline whole-cycle flow in lesions with less than 50% diameter stenosis80. 
Similar results were recently reported by Sen et al in the CLARIFY study, which 
showed that FFR hyperaemic distal coronary resistance is only significantly lower 
than baseline iFR resistance in vessels without flow-limiting disease39. Finally, a 
large variability in microcirculatory resistance measured with thermo-dilution has 
recently been demonstrated in coronary vessels with intermediate stenoses81 
supporting the idea that an inconsistent inter-patient response to adenosine is 
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one of the main responsible for the variable magnitudes of hyperaemic flow 
achieved during FFR calculation39. In agreement with these studies, we found 
that hyperaemic flowFFR is on average only higher than the baseline flowiFR in 
patients with FFR > 0.75. Therefore, in patients undergoing invasive functional 
assessment of coronary disease in clinical practice, adenosine administration (IV 
or IC) only significantly increases coronary flow above baseline diastole in non-
obstructing, FFR-negative stenoses. In the remaining clinically relevant 
significant lesions, the baseline diastolic flow of auto-regulatory vasodilatation 
appears to suffice82. 
6.4.3 Pressure-flow diagnostic conflicts 
Our study also contributes to our understanding of the mechanisms behind 
pressure-flow diagnostic conflicts83. Induction of maximal hyperaemia is a pre-
requisite for the calculation of both FFR and CFVR30. However, as their values 
move in opposite directions when hyperaemic flow increases (Figure 6.1) for any 
given stenosis and fixed baseline flow, an improvement in hyperaemic flow would 
paradoxically lead to a “worse” FFR result (and vice-versa). Therefore, because 
the individual response to adenosine has been shown to vary significantly 
amongst patients with CAD35, 36, 39, diagnostic disagreements between pressure 
indices and CFVR are expected to occur if both are measured during 
hyperaemia. Our results support this concept, as we found that the closer 
relationship between iFR and CFVR is lost when iFR is measured during 
adenosine administration (iFRa), suggesting the hyperaemic response itself (and 
not the utilisation of whole-cycle physiology) is the most likely cause of conflicts 
between pressure indices and CFVR.  
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It is already acknowledged that conditions which restrict hyperaemic flow (severe 
ventricular hypertrophy, increased left ventricular pressures and microvascular 
obstruction) can make FFR values artificially higher and challenging to interpret 
clinically84, 85. Our findings also help to clarify the physiological mechanisms 
behind the other discordant group. In a small proportion of stenoses, ischaemic 
FFR values (≤ 0.75) may be generated by high hyperaemic flow rates and higher 
than average CFVR (Table 6-3 and Figure 6.5 and Figure 6.6). Specifically, the 
generation of large hyperaemic gradients in stenoses with normal iFR values (> 
0.9), identify a particular subgroup of patients with high CFVR (Figure 6.1, 
mechanism 2 and Figure 6.3). These lesions demonstrate, on average, 
magnitudes of hyperaemic flow velocities equal to what is observed in stenoses 
with FFR > 0.80, both significantly higher than flow velocities seen in the overall 
population of FFR significant lesions (≤ 0.75) (Figure 6.3). Also, these cases 
have been shown to have five year outcome similar to vessels with concordant 
FFR and CVFR results (FFR>0.75, CVFR>2.0)32. Although uncommon (less than 
5% of cases in this cohort), this phenomenon has been previously described in 
studies using PET35, Doppler36 and thermodilution-derived CFR81. 
The concept that a large coronary pressure gradient only present during 
hyperaemia is a result of high CFVRs has previously been identified and 
explored by independent groups. Akasaka et al and MacCarthy et al have 
independently demonstrated that a good correlation with CFVR can be obtained 
from pressure alone, by measuring the changes in pressure gradients, from 
baseline to hyperaemia86. Indeed, Johnson et al, using data derived from a large 
PET dataset35, 83, specifically warned against the universal application of a fixed 
FFR cut-off of 0.75-0.8 to detect ischaemia in all patients, as this threshold could 
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vary depending on the inter-individual variability of CFVR and the extent of 
microvascular disease in any given population. Therefore, stenoses with a large 
discrepancy between high iFR and low FFR values represent, on average, a sub-
group of lesions with high CFVR in which hyperaemic coronary flow is not 
significantly limited.  In such cases, care should be taken when interpreting the 
low FFR values as evidence of ischaemia.  Randomised clinical trials need to be 
performed to prospectively evaluate outcomes in such subgroup of stenoses. 
6.5 Clinical implications  
Utilisation of invasive functional evaluation of coronary disease has significantly 
increased with the development of FFR, largely because of the simplification 
brought by use of pressure-only methods. However, adoption of FFR remains 
low (6-8%)33, 60. The reasons are multi-factorial and include difficult access to 
adenosine in some geographies and concerns over increased procedural time 
and costs, particularly in patients with 3-vessel disease33. Therefore, the 
demonstration that iFR, a pressure-only index which does not require adenosine, 
has a close association with underlying CFVR, is supportive of its potential future 
role as a tool to guide decision-making in CAD. By eliminating the need for 
hyperaemia, iFR could make coronary functional assessment simpler and deliver 
the known benefits of physiology-guided revascularisation to many more patients 
with CAD. Clinical trials will evaluate the impact of iFR-guided decisions on 
clinical outcomes. The FLAIR study will prospectively compare iFR and FFR-
guided strategies in 2500 patients with stable coronary artery disease. 
.                 
 
6.6 Limitations  
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Our study has limitations. Firstly, our analysis was performed retrospectively in 
previously recorded haemodynamic traces. However, our study represents the 
largest comparison of pressure-only indices against invasive flow in patients with 
CAD, meticulously recorded in centres dedicated to the measurement of 
coronary haemodynamics.     
This study used CFVR as a reference comparison, an index which, despite its 
established diagnostic and prognostic value in coronary disease, is not widely 
used in the catheterisation laboratory for clinical decision-making.  For the 
interrogation of intermediate stenoses, CFVR has been largely replaced by a 
simple pressure ratio (FFR), because of its easier applicability and demonstrated 
superiority over angiography13, 14. Clinical application of invasive CFVR is now 
largely limited to evaluation of coronary microvascular function42 and scientific 
research. These practical aspects of CFVR utilisation, however, do not diminish 
its biological value as flow-based discriminator, especially when measurements 
are performed by experienced operators in high-volume centres which 
participated in this study. Both FFR and CFVR have demonstrated to be useful to 
guide revascularisation, with similar rates of MACE42, and equal ability to detect 
myocardial ischaemia in the presence of coronary stenoses51, 77. Also, iFR and 
FFR were obtained from the same haemodynamic trace in which CFVR was 
measured. Therefore, technical limitations to CFVR should equally affect its 
relationship with both iFR and FFR. Finally, although a CFVR value of 2.0 is the 
most widely accepted cut-off and the majority of our analysis is based on such 
value, we have also performed comparisons with multiple CFVR cut-offs to 
reduce the potential bias of choosing a single dichotomous cut-off for the 
reference test.     
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We used a ratio of flow velocities to calculate flow reserve, which assumes the 
cross-sectional area of the vessel is maintained from baseline to hyperaemia. 
This is achieved by the administration of intracoronary GTN at the start of the 
recordings. Significant changes in underlying flow rate are unlikely to occur as a 
result of changes in vessel diameter during adenosine administration23.     
Different adenosine routes (intravenous versus intracoronary) and doses were 
used to induce coronary hyperaemia. Although this might be seen as a potential 
limitation, it better reflects the real-world utilisation of FFR in clinical practice, 
making our results directly applicable to patients with CAD. Although larger 
doses of intracoronary adenosine can be used, the dose used in this study (20-
60mcg) achieved the same magnitude of hyperaemic flow velocity as 
140mcg/Kg/min of intravenous adenosine infusion, regime used in FAME and 
FAME II. Also, recent large clinical cohorts have shown the clinical benefits of 
FFR when utilising such lower doses in clinical populations87. A more detailed 
discussion on the optimal dose of vasodilators to achieve maximal coronary 
hyperaemia has recently been provided by van de Hoef et al76.           
We performed a specific ROC analysis on the performances of iFR and FFR 
against CFVR in the intermediate 0.6 - 0.9 FFR range. Whether such narrower 
range of FFR values represents a particularly important sub-group of lesions is 
debatable, considering that cardiac events are lower in this region when 
compared to more severe stenoses13, 87. Because recent reports suggested that 
such intermediate range is important88, our analysis aimed to demonstrate that 
the diagnostic agreement between iFR and CFVR was maintained when FFR 
values fell between 0.6 and 0.9. However, we did not perform any correlation 
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analysis in such restricted range, as this can artificially lower the relationship 
between any two tests.      
A word of caution is important when using pressure indices as an estimation of 
underlying coronary flow. Although different in many physiological aspects, both 
iFR and FFR use a trans-coronary ratio of pressures as a means of estimating 
the underlying reduction in coronary flow. Whilst this pressure-only approach 
facilitates clinical application of physiology in the catheterisation laboratory, it 
should not be seen as a biological equivalent of direct measurement of coronary 
flow.       
Finally, the demonstration that, when compared to FFR, iFR has a closer 
relationship with underlying CFVR should not be interpreted as superiority of one 
index over another. In studies of coronary physiology and ischaemic heart 
disease, all inter-test comparisons are limited by the lack of a true gold standard 
for the detection of myocardial ischaemia. Although extensively validated as a 
measure of myocardial perfusion, CFVR is only one of several available methods 
to measure it and is currently not the most commonly used tool in the 
catheterisation laboratory. Therefore, our findings cannot infer any clinical 
benefits of iFR over FFR in clinical decision-making. We have simply 
demonstrated a close diagnostic agreement between iFR and underlying 
coronary flow, which helps its validation as a potential test to detect flow-limiting 
stenoses. Our findings help to set the physiological foundations for future studies 
with clinical outcomes, which will evaluate the merits of iFR as a clinical decision-
making tool.         
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6.7 Conclusion 
When compared to FFR, iFR agrees more closely with underlying coronary flow 
reserve, a strong predictor of events in patients with coronary artery disease. 
Because it does not require the induction of hyperaemia for its calculation, iFR 
may simplify functional evaluation of coronary stenoses and enable expansion of 
physiology-guided revascularisation to many more patients with coronary artery 
disease.  
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6.8 Tables  
Number of stenoses (patients) 216 (186)
Age, yrs 61±11
Male % 75
Co-morbidities, %
Hypertension 47
Hypercholesterolaemia 73
Smoking history 44
       Diabetes 22
Chronic renal disease 2
Severe LV dysfunction 
(EF<30%) 1
Clinical presentation, %
Stable angina 98
Unstable angina 2
Coronary anatomy, %
Single vessel CAD 52
Multivessel CAD 48
LAD 56
LCx 18
RCA 24
Other 2
Proximal vessel 35
Diameter stenosis, % ± SD 56 ± 16
Adenosine route, %
Intravenous 35
Intracoronary 65
EF = Ejection Fraction; CAD = Coronary artery disease; LAD = Left 
anterior descending artery; LCx = Left circumflex artery; RCA = 
Right coronary artery; SD = Standard deviation of the mean. 
Smoking history includes current and previous cigarette smoking. 
 
Table 6-1: Demographic and angiographic data 
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  CFR = coronary flow velocity reserve; FFR = fractional flow reserve; iFR = instantaneous wave-free ratio; AUC = area under the ROC curve.   
 
 
CFVR 
Cut-off 
Whole sample  
(186 patients, 216 observations) 
0.6 - 0.9 FFR range  
(113 patients; 129 observations)  
iFR AUC FFR AUC p value iFR AUC FFR AUC p value 
1.7 0.89 [0.84, 0.93] 0.80 [0.73,0.87] <0.001 0.86 [0.79,0.93] 0.67 [0.56, 0.77] <0.001 
2.0 0.82 [0.76, 0.88] 0.72 [0.65, 0.79] <0.001 0.78 [0.69, 0.86] 0.59 [0.48, 0.69] <0.001 
2.5 0.79 [0.74, 0.85] 0.71 [0.64, 0.78] 0.002 0.74 [0.65,0.83] 0.55 [0.45, 0.66] <0.001 
3.0 0.77 [0.70, 0.84] 0.69 [0.59, 0.79] 0.057 0.76 [0.67, 0.86] 0.54 [0.42, 0.67] <0.001 
Table 6-2: Diagnostic agreement between pressure-only indices and different cut-offs of coronary flow velocity reserve 
CFVR = coronary flow velocity reserve; FFR = fractional flow reserve; iFR = instantaneous wave-free ratio; AUC = area 
under the ROC curve   
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Table 6-3: Underlying coronary flow in different sub-groups of stenoses 
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6.9 Figures          
           
           
           
           
           
           
           
      
 
Figure 6.1: How can a low FFR value be generated? 
Schematic representation of the relationship between pressure gradient and flow 
across a coronary stenosis. The same FFR value (in this example 0.75, equivalent to 
a pressure drop of 25mmHg) can be generated via two different mechanisms. In (1), 
even a small magnitude of hyperaemic flow is sufficient to generate a 25mmHg drop 
in a severe, flow-limiting lesion. In (2), much higher hyperaemic flow rates are needed 
for the same 25mmHg to be created in a mild stenosis. Stenosis (1) is very likely 
causative of myocardial ischaemia, whilst stenosis (2) is by definition not significantly 
flow-limiting, despite displaying the same FFR classification.         
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Figure 6.2: Diagnostic performance of pressure-only indices against coronary flow reserve 
(A) When compared to fractional flow reserve (FFR), instantaneous wave-free ratio (iFR) has better 
diagnostic agreement with coronary flow velocity reserve (CFVR).  Scatter plots between FFR and 
CFVR (B) and between iFR and CFVR (C) are shown, with the dashed horizontal line demarcating a 
CFVR cut-off of 2.0.  
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Figure 6.3: Measurement of iFR and FFR for the identification of stenoses with abnormal 
CFVR 
iFR measurement identifies lesions with low underlying CFVR (green panel). Adenosine 
administration and FFR calculation adds no discrimination over baseline iFR results (red panel) 
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Figure 6.4: Effects of adenosine on coronary flow in patients with coronary 
disease 
Adenosine-induced augmentation of coronary flow is variable across the spectrum of 
disease severity (top panel, scatter plot). Whole-cycle hyperaemic flow (FFR flow) is 
not higher than baseline mid-diastolic wave-free flow (iFR flow) in functionally 
ischaemia-inducing stenoses, when FFR ≤ 0.75 (A). FFR flow becomes higher than 
iFR flow only in mild, FFR-negative lesions (B).   
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Figure 6.5: Scatter plot between iFR and FFR, with colour-coded CFVR 
High iFR values are associated with high magnitudes of coronary flow velocity reserve (CFVR) (A). The sub-group of lesions with high 
iFR values and significantly low FFR values (FFR ≤ 0.75) demonstrate, on average, particularly high CFVR (grey box, B).  
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Figure 6.6: Examples of cases in which low FFR values are generated by high 
magnitudes of hyperaemic flow 
In all three cases, baseline instantaneous wave-free ratio (iFR), coronary flow 
velocity reserve (CFVR) and hyperaemic stenosis resistance index (HSR, another 
flow-based index of disease severity) were normal, indicating a mild, not flow-limiting 
stenosis. In (C) a SPECT myocardial perfusion scan also confirms the absence of 
myocardial ischaemia. These lesions should not be considered causative of 
ischaemia, despite their low FFR value.   
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7 Synthesis 
In this thesis I have extended the validation of iFR as an index of coronary stenosis 
severity, by further exploring its clinical relationship with FFR and by studying its 
underlying haemodynamics and its relation to coronary flow reserve.    
 
7.1 iFR, FFR and stenosis classification  
Expanding on the initial analysis presented on the ADVISE study, I have evaluated 
the classification agreement between iFR and FFR in a large clinical sample of 339 
coronary stenoses. This analysis demonstrated that in patients with CAD undergoing 
invasive functional assessment of coronary lesions, iFR and FFR agreement in 
stenosis classification is high (80%), to a magnitude compared to the agreement 
between repeated FFR measurements (86%). In clinical practice therefore, iFR 
agrees with FFR 94% as well as FFR agrees with itself in repeated measurements. 
Also, in this initial study I demonstrated the large influence the distribution of disease 
severity of the underlying sample can have in the agreement between iFR and FFR 
and between repeated FFR measurements. This is extremely relevant because early 
validation studies and clinical trials are commonly performed in samples with a case-
control fashion of disease distribution, and therefore yield higher magnitudes of 
classification agreement between methods. Clinical samples, on the other hand, are 
predominantly formed by intermediate values of FFR, straddling its cut-off, which 
results in lower magnitudes of agreement between tests (iFR and FFR) and between 
repeated measurements of the reference standard (FFR).            
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7.2 The concept of the V-test: a sample independent statistical measure of 
accuracy 
In chapter 3 I sought to establish the classification agreement (accuracy) between 
iFR and FFR and compare it to the agreement between repeated FFR 
measurements in different samples. However, direct comparisons between 
accuracies derived from different studies are invalid because the distribution of 
underlying disease severity affects the relationship between tests. To circumvent this 
limitation I have developed a new sample-independent statistical approach to the 
calculation of diagnostic accuracy, the V-Test, presented in details in chapter 4. 
Using a simple conceptual model of disease (the diagnosis of 
hypercholesterolaemia) and data generated using statistical software I demonstrated 
how values of diagnostic accuracy are largely influenced by the distribution of 
underlying disease severity. Finally, I presented a simple solution: the V-test, a 
methodology which adjusts the values of accuracy according to the underlying 
distribution of values. Although the concept of the V-test was initially used to better 
understand the relationship between iFR and FFR, it can be applied to any direct 
comparison between two methods of clinical measurement, in which values of 
classification agreement (accuracy) are being evaluated.     
 
7.3 Vasodilator-sparing potential of a hybrid iFR - FFR decision-making 
approach  
FFR utilisation is supported by trials with clinical outcomes, but its low adoption is 
partly caused by its dependence on the induction of hyperaemia and the need for 
vasodilator administration. iFR is a novel vasodilator-free index which has close 
agreement with FFR but no trial evidence to support its use as a sole guide to clinical 
decisions. In chapter 5 I presented the idea of a hybrid decision-making strategy, in 
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which both iFR and FFR are used together in a common diagnostic pathway. This 
hybrid approach permits the benefits of both techniques to be immediately applied to 
patients: the safety and prognostic implications of a high agreement with FFR 
classification of lesions (95%) and a significant reduction (57%) in the need for 
vasodilator administration. In practice, it means that a 3 vessel physiological 
assessment can be performed with adenosine only being given to one interrogation. 
Whilst we wait for the results of clinical outcome trials which will evaluate the merits 
of iFR on its own, the hybrid iFR-FFR approach allows the benefits of physiological 
interrogation to be expanded to more patients with CAD.      
 
7.4 iFR and its closer relationship with underlying coronary flow reserve 
In the final study of this thesis, I have explored the relationship between pressure 
indices iFR and FFR with underlying coronary flow reserve (CFR). Several important 
physiological observations can be drawn from this study, relevant to the clinical 
utilisation of physiological indices. Firstly, when iFR and FFR disagree in the 
classification of stenosis, iFR has a closer relationship to underlying CFR. This is 
important because it provides indirect insights into the safety of iFR utilisation, as 
CFR provides the most robust prognostic discrimination on the risk of major cardiac 
events, including death, myocardial infarction and the need for urgent 
revascularisation. Secondly, a detailed analysis of phasic coronary flow supported 
the previous findings of CLARIFY: adenosine can only significantly increase coronary 
flow above baseline diastole (iFR diastolic window) in mild, FFR-negative stenoses. 
This finding challenges the need for adenosine administration during physiological 
interrogation, as baseline diastolic flow appears to provide sufficient hyperaemia. 
Finally, I demonstrated that large numerical disagreements between iFR and FFR 
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are driven by high magnitudes of hyperaemic flow and high CFR. Therefore, in the 
majority of cases in which iFR is very high and FFR very low, stenoses do not 
appear to be truly flow-limiting, which questions the gold standard status of FFR as a 
marker of myocardial ischaemia and flow limitation. This study provides further 
physiological justification on the need for outcome trials to evaluate the role of iFR as 
a sole guide to coronary revascularisation.           
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8 Conclusion 
Across different samples of disease severity distribution, iFR demonstrates a close 
diagnostic relationship with FFR, with most disagreements in lesion classification 
occurring close to their cut-offs.  
Large numerical disagreements between iFR and FFR are driven by high 
magnitudes of coronary flow and higher than average CFR.  iFR, therefore, has a 
closer relationship with underlying coronary flow reserve, which provides insight into 
the safety of its future application as a sole guide to clinical decisions.    
Until outcome trials evaluate the merits of iFR as an independent clinical tool, iFR 
and FFR can be used together in hybrid decision-making strategy, which could 
immediately spare a large proportion of patients from the need of vasodilator, whilst 
maintaining the safety of FFR classification of lesions. 
8.1 Future directions 
This thesis simply extended the initial validation work on the development of iFR. 
Therefore, there are still several unexplored areas from which further studies can 
develop upon. Broadly, this work was performed in patients with stable coronary 
disease without haemodynamic disturbances or significant valvular disease. An 
important and under explored area of research is the use of invasive physiology in 
conditions of haemodynamic fluctuations, such as acute coronary syndromes, 
cardiogenic shock and severe valvular disease. The role of pressure-only resting 
indices such as iFR and hyperaemic indices such as FFR will need to be 
investigated in such scenarios together with the benefits of measuring flow over 
pressure-only assessment. 
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